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Aims and Objectives 
 
 
 
 
 
1. To study the incidence of immune reconstitution inflammatory syndrome 
(IRIS) in a cohort of HIV infected patients, newly initiated on highly 
active anti-retroviral therapy (HAART). 
2. To describe the syndrome of IRIS. 
3. To identify predictive factors for IRIS. 
 
 
 
 
 
 
 
 
 
 
 
Literature review 
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Introduction:  
Immune reconstitution inflammatory syndrome (IRIS) is the syndrome of paradoxical 
worsening of a known OI (OI) or appearance of signs of a new OI following initiation of 
highly active anti-retroviral therapy (HAART) in patients with Acquired 
Immunodeficiency Syndrome (AIDS). This is thought to result from restored immunity to 
specific infectious and non-infectious antigens. This phenomenon was first noticed when 
zidovudine monotherapy was associated with atypical and localised presentations in 
patients with Mycobacterium avium intracellulare (MAC)(1, 2). This was initially 
described in relation only to OIs but its definition has been expanded over the last few 
years to include certain autoimmune diseases such as grave’s disease(3), rheumatic 
diseases(4), sarcoidosis(5) and malignancies(6). OIs associated with IRIS include 
tuberculosis(7-9), atypical mycobacterial infections(1), cytomegalovirus(CMV) 
retinitis(10), Pneumocystis jirovecii pneumonia(11, 12), herpes zoster(13), cryptococcal 
meningitis(14, 15), progressive multifocal leukoencephalopathy(PMLE)(16) and viral 
hepatitis(17). The manifestations of IRIS may be diverse depending upon the underlying 
OI and degree of inflammation. Introduction of ART has led to a significant decline in 
OIs associated with AIDS(18).  However, delayed reconstitution of immunity may also 
contribute to OIs appearing within the first six months after initiation of ART which have 
to be distinguished from IRIS(19). The incidence of new OIs appears to be highest in the 
first three months following initiation of HAART. These may include OIs secondary to 
persistent immunodeficiency and OIs unmasked due to immune reconstitution(19). 
Treatment of immunodeficient patients with highly active antiretroviral therapy 
(HAART) appears to restore pathogen-specific immune responses resulting in prevention 
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or regression of diseases caused by opportunistic pathogens. However restoration of 
pathogen specific immunity may be associated with paradoxical worsening and 
appearance of previously subclinical infections following initiation of ART, which is the 
phenomenon of IRIS(20).  Many of these disease episodes are associated with the 
presence of a pathogen-specific immune response and a more exaggerated inflammatory 
response than is usually present in patients with OIs.  
 
The overall incidence of IRIS is unknown, but may be dependent on the population 
studied and the background prevalence of OIs(21). Treatment for IRIS is largely 
supportive and includes treatment of the identified OI and use of anti-inflammatory 
agents such as steroids.  
 
Several predictive factors for IRIS have been identified in small retrospective cohort 
studies. However, few prospective studies have been done to identify the risk factors for 
development of IRIS. In view of the diversity in presentation and incidence of IRIS 
between populations, local studies are required in India to examine its incidence, clinical 
characteristics and risk factors.   
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Types of IRIS 
Jevtovic et al. described various OIs presenting as IRIS including dermatomal herpes 
zoster, pulmonary tuberculosis , tuberculous exudative pericarditis, tuberculous 
lymphadenitis, cerebral toxoplasmosis, PML, inflamed molluscum, inflamed Candida 
albicans angular cheilitis, genital herpes simplex, tinea corporis, CMV retinitis, CMV 
vitritis and HBV or HCV infection(22). In other retrospective studies also the spectrum of 
IRIS was similar(23, 24). Ratnam et al. also described cases of pneumocystis pneumonia 
and Kaposi’s sarcoma presenting as IRIS(2). The following are the various types of 
infectious and non-infectious diseases associated with IRIS(20): 
 
Table 1. Infectious and non-infectious causes of IRIS in HIV-infected patients 
Infectious Etiologies Non-infectious etiologies 
Mycobacteria Rheumatologic/Autoimmune 
     Mycobacterium tuberculosis       Rheumatoid arthritis  Systemic lupus   
erythematosis(SLE)  
      Mycobacterium leprae      Graves disease , Autoimmune thyroid disease  
     Mycobacterium avium complex  Sarcoidosis & granulomatous reactions  
     Other mycobacteria   
Cytomegalovirus  AIDS-related lymphoma  
Herpes viruses Guillain-Barre syndrome (GBS)  
     Herpes zoster virus  Interstitial lymphoid pneumonitis  
     Herpes simplex virus   
     Herpes virus-associated Kaposi's                   
     Sarcoma  
Cryptococcus neoformans   
Pneumocystis jirovecii pneumonia (PCP)   
Histoplasma capsulatum   
Toxoplasmosis   
Hepatitis B virus   
Hepatitis C virus   
Progressive multifocal leukoencephalopathy   
Parvovirus B19   
 8
Strongyloides stercoralis infection  & other 
parasitic infections   
Molluscum contagiosum & genital warts   
 
Adapted from Murdoch et al. AIDS Research and Therapy 2007 
Epidemiology of IRIS 
Several studies have attempted to study the incidence of IRIS. The incidence of IRIS 
depends on the underlying prevalence of OIs in a population, degree of 
immunodeficiency and other host genetic factors(20). The incidence of specific IRIS may 
also vary between different populations. The following are studies on patients to 
elucidate the incidence of IRIS and their characteristics: 
 
 
Table 2: Epidemiological studies on IRIS 
Authors 
 
 
 
 
 
Place/ 
Country 
Patients selected Percentage 
of patients 
with IRIS 
Duration 
of 
follow 
up 
Median time 
of 
occurrence 
Incidence studies on overall incidence of IRIS 
 
Puthanakit et 
al(25) 
 
Thailand 
 
Prospective study: 
HIV positive 
children with CD4 
percentage <15% 
initiated on ART 
 
 
19% 
(29/153) 
 
48wks 
 
4wks (2-31 
wks) 
Ratnam et al 
(24) 
London, 
UK 
Retrospective 
study: ART naive 
patients 
 
22% 
(44/199) 
6 
months 
12weeks(4-
24wk) 
M.A. French 
et al(23) 
Perth, 
Australia 
Retrospective 
study: HIV 
infected patients 
commencing 
25% 
(33/132) 
among 
HAART 
30 wks <8wks in 
67% 
patients 
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HAART (naïve 
and experienced) 
 
responders 
Jevtovic et al. 
(22) 
Belgrade Retrospective 
cohort: ART naive 
patients 
16.7% 
(64/389) 
---- 4.6months(2
-12) 
Authors 
 
 
 
 
Place/ 
Country 
Patients selected Percentage 
of patients 
with IRIS 
Duration 
of 
follow 
up 
Median time 
of 
occurrence 
Incidence studies on OI specific incidence of IRIS 
Shelburne et 
al(26) 
Houston, 
Texas 
Retrospective 
cohort: HIV and 
M.Tb, M. avium 
and Cryptococcus 
coinfection 
31.7% 
(57/180) 
2.17 
person 
years 
46 days (3-
658) 
Narita et al (7) Miami Prospective cohort 
group1 HIV+TB 
initiated on ART 
36% (12/33) ---- ---- 
Bourgarit et al 
(27) 
Paris, 
France 
Prospective case 
series: 19 
consecutive 
untreated HIV-TB 
coinfected patients 
37% (7/19) 3months ----- 
Kumaraswamy 
N et al (28) 
Chennai, 
India 
Prospective cohort 
study: HIV and TB 
co-infected 
patients 
commencing 
HAART 
7.6% 
(11/144); 
15/100 
person 
years(incide
nce) 
72 
person 
years 
42 days(10-
89d) 
Cheng et al 
(29) 
Hong 
Kong 
Prospective series: 
HIV and TB 
15% 
(16/104) 
--- 56days (20-
109) 
Breton et 
al(30) 
Paris, 
France 
Retrospective 
study: ART naive 
patients with HIV 
and TB coinfection 
43% (16/36) 2-65 
months 
12days (2-
14) 
Navas et al 
(31) 
Spain Retrospective 
study: HIV and TB 
co-infected 
patients 
35% (6/17) --- ---- 
Lortholary et 
al. (32) 
France Retrospective 
multicentre study: 
HIV and 
cryptococcus co-
infected patients 
commencing 
Cryptococca
l IRIS: 8.3% 
(10/120) 
239 
person 
years 
8 months 
(2-37 
months) 
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HAART 
 
Incidence of IRIS in patients newly initiated on HAART varies from 16 to 25% (Table 
2.). However, the incidence of IRIS in patients with HIV-TB co-infection may be 
variable ranging from 35 to 43%. There is only one prospective study from India which 
showed an incidence of 15 per 100 person years among patients with HIV-TB co-
infection initiated on ART (28). (Table 2.) 
 
Definitions of IRIS 
 
The definition of IRIS has been a very controversial issue (21),(33). Most authors agree 
that IRIS is the new occurrence or clinical deterioration of an already existing OI in HIV-
infected patients as a direct result of the enhancement of immune responses to those 
dormant pathogens during HAART. It occurs as an exaggerated immune response 
specific to endogenous antigens or pathogens rather than a new occurrence of exogenous 
OIs. The problem with the definition is the difficulty in establishing a causal relationship 
between initiation of HAART and onset of symptoms or signs.  Worsening of symptoms 
and signs after initiation of HAART has to be distinguished from deterioration of OIs as a 
complication of residual immunodeficiency, inadequate treatment of primary OI or drug 
reactions.  
 
Shelburne et al. laid down the first case definition for IRIS which has been adapted and 
used in several studies designed to assess the characteristics and incidence of certain 
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types of IRIS (32),(34). Recently, consensus case definitions have been laid down for 
paradoxical tuberculosis-associated IRIS, ART-associated tuberculosis, and unmasking   
tuberculosis-associated IRIS applicable to resource limited settings(35). The following 
are various definitions that have been used for IRIS in epidemiological studies:  
Table 3. Definitions of IRIS used in epidemiological studies 
Author Case definition for IRIS used 
Shelburne et al. 
(26),(36) 
1. Initial response to treatment of previous OI 
2. Recurrence of initial symptoms or new symptoms after 
initiation of ART 
3. symptoms or investigations compatible with an inflammatory 
process 
4. Rising CD4 count and falling HIV RNA levels 
5. Symptoms could not be explained by a newly acquired 
infection, by the expected clinical course of a previously 
recognized infectious agent, or by side effects of therapy. 
 
Breton et al.(30) 
 
1. Reappearance or worsening of previous manifestations or new 
manifestations despite adequate treatment of OI 
2. Disappearance of symptoms after interruption of antiretroviral 
therapy and recurrence of symptoms after re-initiation of 
antiretroviral therapy 
3. Positive results of bacteriological examination or cultures in 
organ with suspected OI 
4. Histological evidences of inflammation (e.g. granulomatous 
inflammation in tuberculosis) 
 
French et al (37) 
 
A. Major criteria: 
1. Atypical pattern of OIs or tumors in patients responding to 
ART (exaggerated inflammatory reaction/atypical 
inflammatory response/localised disease/progression of organ 
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dysfunction or enlargement of pre-existing lesions after 
improvement with specific antimicrobial therapy prior to 
commencement of ART with exclusion of drug adverse effect 
or new diagnosis) 
2. Decrease in plasma HIV RNA by>1 log10 copies/ml 
B. Minor criteria 
1. Increased CD4 count after ART 
2. Increase in immune response specific to pathogen 
3. Spontaneous resolution of disease without specific anti-
microbial therapy with continuation of ART 
Diagnosis requires presence of 2 major criteria or the first major 
criteria with 2 minor criteria 
 
Colebunders et 
al. (33) 
 
TB IRIS: Case definition 
1. Radiological examinations showing worsening or emergence 
of intra-thoracic lymphadenopathy, pulmonary infiltrates, 
pleural effusions, abdominal lymph nodes, 
hepatosplenomegaly 
2. A good virological response and/or an increased CD4  
lymphocyte count, and/or conversion of Tuberculin skin 
test(TST) from negative to positive and/or adequate adherence 
to ART and TB treatment. 
3. Clear exclusion of other conditions that could explain the 
clinical manifestations of the patient, such as TB treatment 
failure or other concomitant infections, tumours or allergic 
reaction 
 
Meintjes et 
al.(35)  
 
Consensus case definition for paradoxical TB associated IRIS 
(A) Antecedent requirements 
Both of the two following requirements must be met: 
• Diagnosis of tuberculosis: the tuberculosis diagnosis was 
made before starting ART and this should fulfil WHO 
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criteria for diagnosis of smear-positive pulmonary 
tuberculosis, smear-negative pulmonary tuberculosis, or 
extrapulmonary tuberculosis. 
• Initial response to tuberculosis treatment: the patients 
condition should have stabilised or improved on 
appropriate tuberculosis treatment before ART initiation 
eg: cessation of night sweats, fevers, cough, weight loss. 
(this does not apply to patients starting ART within 2 
weeks of starting tuberculosis treatment since insufficient 
time may have elapsed for a clinical response to be 
reported) 
(B) Clinical criteria 
The onset of tuberculosis-associated IRIS manifestations should 
be within 3 months of ART initiation, reinitiation, or regimen  
change because of treatment failure. 
Of the following, at least one major criterion or two minor clinical 
criteria are required: 
Major criteria  
• New or enlarging lymph nodes, cold abscesses, or other 
focal tissue involvement eg, tuberculous arthritis 
• New or worsening radiological features of tuberculosis 
(found by chest radiography, abdominal ultrasonography, 
CT, or MRI) 
• New or worsening CNS tuberculosis (meningitis or focal 
neurological deficit) 
• New or worsening serositis (pleural effusion, ascites, or 
pericardial effusion) 
 
Minor criteria 
• New or worsening constitutional symptoms such as fever, 
night sweats, or weight loss 
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• New or worsening respiratory symptoms such as cough, 
dyspnoea, or stridor 
• New or worsening abdominal pain accompanied by 
peritonitis, hepatomegaly, splenomegaly, or abdominal 
adenopathy 
(C) Alternative explanations for clinical deterioration must be 
excluded if possible 
• Failure of tuberculosis treatment because of tuberculosis 
drug resistance 
• Poor adherence to tuberculosis treatment 
• Another OI or neoplasm (it is particularly important to 
exclude an alternative diagnosis in patients with smear-
negative pulmonary tuberculosis and extrapulmonary 
tuberculosis where the initial tuberculosis diagnosis has 
not been microbiologically confirmed) 
• Drug toxicity or reaction 
 
Consensus case definition for unmasking TB associated IRIS 
• Patient is not receiving treatment for tuberculosis when ART 
is initiated and then presents with active tuberculosis within 3 
months of starting ART 
AND one of the following criteria must be met 
• Heightened intensity of clinical manifestations, particularly if 
there is evidence of a marked inflammatory component to the 
presentation. Examples include tuberculosis lymphadenitis or 
tuberculosis abscesses with prominent acute inflammatory 
features, presentation with pulmonary tuberculosis that is 
complicated by respiratory failure due to adult respiratory 
distress syndrome, and those who present with a marked 
systemic inflammatory syndrome related to TB 
• Once established on TB treatment, a clinical course that is 
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complicated by a paradoxical reaction 
 
Significant diagnostic criteria common to all the above definitions are summarised 
below:  
1. Temporal association between starting HAART regimen and subsequent 
development of clinical phenomena.  
2. Clinical picture: Unusual clinical manifestations or unexpected clinical course 
with an exaggerated inflammatory response.  
3. Evidence of preceding immune restoration: 
a. A rise in blood CD4 lymphocyte count. 
b. Preceding fall in HIV viral load. 
c. Restoration of cutaneous hypersensitivity to mycobacterial 
antigens (PPD or MAC antigen) or increased in-vitro T-cell 
proliferative responses to PPD or MAC antigen. 
d. Histopathological or cytological appearances of unexpectedly 
florid cell-mediated immune response within tissue samples.  
  
4. Exclusion of alternative explanations—eg, drug resistance, non-compliance with 
treatment for the OI, drug reactions 
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Although most definitions for IRIS exclude patients who have been pre-treated with 
regimens of ART, there is more awareness now that even patients who have received 
HAART before and have failed various regimens can develop IRIS with a new regimen. 
There is a movement to include such cases in the case definition of IRIS (33) . However,  
being HAART naïve has been identified as one of the risk factors for IRIS and such 
patients appear to be more at risk than others (26).  
 
Some case definitions have included subsidence of clinical symptoms after interrupting 
HAART (30). However, this may not be an important part of the case definition as 
interruption of HAART is not desirable or beneficial. 
 
Risk factors for development of IRIS 
The risk factors for IRIS reflect the pathogenesis of this phenomenon. It seems to arise 
from an interaction between antigen burden, host genetic susceptibility factors and 
immune dysregulation (37). 
 
Various cohort and retrospective have examined the possible predictors for development 
of IRIS. The differences in study results may be due to differences and limitations in the 
methodology. The predictors identified include low  baseline CD4 counts(22-25, 38), 
high baseline viral load (23), increase in CD4 count at one month, younger age(24), low 
CD4:CD8 ratio(24), increase in CD4:CD8 ratio (30), initiation of ART soon after 
diagnosis of OI (26), rapid decline in viral load(26, 38) and use of boosted protease 
inhibitors(38).  These studies have been briefly outlined below:  
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Table 4. Risk factors and predictors of IRIS 
Study Characteristics Positive predictors Negative 
predictors 
Non-significant 
associations 
Puthanakit et 
al (25) 
Prospective 
cohort study 
 Low 
baseline 
CD4 count 
  Baseline viral 
load 
 Viral load decline 
 Rise in CD4 
count 
Manabe et 
al.(38) 
Case control 
study 
 Boosted 
protease 
inhibitor 
 
 Nadir CD4 
count<100 
 Higher 
baseline 
viral load 
 Plasma viral 
load decline 
of more 
than 2.5 
logs at time 
of IRIS 
 Absolute 
rise in 
CD4 
count 
 
Jevtovic et al 
(22) 
Retrospective 
cohort study 
(n=389) 
 CD4<100 A rise in CD4 
count above 400 
at 4-6 months 
 CD4 count rise 
 Viral load decline 
 Previous OIs 
 
Shelburne et 
al (26) 
Retrospective 
chart review; 
HIV, M.Tb, 
MAC & 
Cryptococcus 
neoformans co-
infected patients 
(n=180) 
 Initiation of 
ART close to 
diagnosis of 
OI 
 Rapid decline 
of viral load 
after HAART 
initiation 
 Male gender 
  Age 
 Race 
 Baseline CD4 
count 
 Baseline viral 
load 
 PI containing 
regimens vs other 
regimens 
 Duration between 
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OI and HAART 
French et al 
(23) 
Retrospective 
study: HIV 
infected patients 
commencing 
HAART ;only 
responders 
included(n=132) 
 Low baseline 
CD4 counts 
 High baseline 
viral load 
  Rise in CD4 count 
 Decline in viral 
load 
 Duration between 
OI and HAART 
Kumarasamy 
et al (28) 
Prospective 
cohort: HIV and 
TB co-infected 
patients 
   Baseline CD4 
 Rise of CD4 count 
 Duration between 
treatment for TB 
and initiation of 
HAART 
Breton et al 
(30) 
Retrospective 
cohort: ART 
naïve HIV and 
TB co-infected 
patients 
 Increase in 
CD4 count 
 Increase in 
CD4:CD8 ratio 
at one month 
 Disseminated 
tuberculosis 
  
Lortholary 
(32) 
Retrospective 
multi-centre 
study: HIV and 
Cryptococcus 
co-infected 
patients initiated 
on HAART 
(n=120) 
 HAART 
initiated within 
60 days of 
diagnosis of 
cryptoccal 
infection 
 Disseminated 
cryptococcosis 
 Fungemia at 
diagnosis 
 Lack of CSF 
sterilisation 
after two 
weeks of 
treatment 
  Gender 
 Age 
 Baseline CD4 
counts 
 Baseline viral 
load 
De Boer et 
al(39) 
Case control 
study (n=34) 
 Rise in CD4 
counts 
  CD4:CD8 ratio 
 Viral load 
 No. of CDC 
events prior to 
HAART 
initiation 
Navas et al 
(31) 
Retrospective 
study: HIV and 
TB co-infected 
patients (n=17) 
 Early initiation 
of ART after 
ATT 
 Better 
virological 
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response 
Narita et al 
(7) 
Prospective 
cohort gp1 
HIV+TB 
initiated on 
ART (n=33) 
 Larger drop in 
viral load after 
initiation of 
HAART 
  Initial CD4 
count 
 Initial CD4 
percentage 
 Initial 
CD4:CD8 ratio 
 Initial viral load 
 Increment in 
CD4 count 
Ratnam et 
al(24) 
Retrospective 
study of patients 
initiating 
HAART 
 Younger 
age 
 CD4 
percentage<
10% 
 CD4:CD8 
ratio<0.15 
  Magnitude of 
increase in CD4 
count over 
24wks 
Lawn et 
al.(40) 
Retrospective 
study of patients 
receiving anti-
TB treatment 
initiated on 
ART (South 
Africa) 
 Low CD4 
count 
 Early 
initiation of 
ART after 
initiation of 
TB 
treatment 
  
 
In summary, the following risk factors for IRIS were identified: 
1. Low baseline CD4 count (22, 23, 25, 38, 40) or percentage (24). 
2. Larger rise in CD4 counts (30, 39) 
3. High baseline viral load (23) 
4. Rapid decline in viral load (7, 26, 31, 38) 
5. Early initiation of HAART after OI (26, 31, 32, 40) 
6. Disseminated tuberculosis (30, 32) 
7. Disseminated cryptococcosis (32) 
8. Male gender (26) 
9. Younger age (24) 
10. Boosted protease inhibitor use (38) 
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Pathogenesis of IRIS 
 
Although IRIS is a well described phenomenon during immune recovery, the 
pathogenesis for IRIS remains unclear. It appears to be the composite of interaction of 
several factors including pathogen load, the rate and magnitude of immune recovery as 
well as genetic factors.  
 
Antigenic stimulus appears to be essential for the development of IRIS. This is indicated 
by studies which demonstrated that disseminated tuberculosis and disseminated 
cryptococcosis are risk factors for development of IRIS indicating that high pathogenic 
burden may contribute to development of IRIS (30, 32).  Antigenic stimulus may be 
infectious or noninfectious; it may be intact or dead organisms. In noninfectious causes of 
IRIS, autoimmunity to innate antigens plays a likely role in the syndrome. 
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The theory that the probability of IRIS depends on the rate and degree of immune 
reconstitution has received attention. There is evidence for quantitative as well as 
qualitative restoration of immunity in the first few weeks following initiation of HAART. 
 
Investigators have examined the association between CD4 cell counts and viral loads and 
the risk of IRIS. Several studies have demonstrated a greater magnitude of rise in CD4 
cells among patients with IRIS in comparison with those who did not develop IRIS (30, 
39). 
 
IRIS seems to be associated with a restitution of antigen specific response. This has been 
demonstrated by restoration of delayed tuberculin responses in several studies(1),(23).  
Initiation of HAART is associated with an increase in CD4 memory cells. Autran et al 
demonstrated a three-phase T cell reconstitution was demonstrated after HAART, with: 
(i) an early rise of memory CD4+ cells, (ii) a reduction in T cell activation correlated to 
the decreasing retroviral activity and (iii) a late rise of "naïve" CD4+ lymphocytes while 
CD8+ cells declined(41). There appears to be an initial and abrupt increase in the 
CD45RO subset of CD4 T cells (memory cells), followed over many months by a more 
subtle increase in the CD45RA subset (naïve T cells). Suppression of viral replication 
reduces the intense immune activation in lymph node tissues that had previously 
sequestered lymphocytes in tissue site. The increase in CD4+ T cells following therapy 
most likely is a combination of initial redistribution from lymph nodes into blood 
where previously activated lymphocytes were sequestered, accompanied by a 
continuous slow repopulation with newly produced naive T-cells(42, 43). Cytokines 
may also have a role in the development of IRIS. Increased levels of interleukin-6 (IL-6) 
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in IRIS patients(44) may explain the exuberant Th1 response to mycobacterial antigens in 
subjects with clinical IRIS (27).  
 
Another pathogenic mechanism for IRIS involves host genetic susceptibility to an 
exuberant immune response to the infectious or noninfectious antigenic stimulus upon 
immune restoration. Although evidence is limited, carriage of specific HLA alleles 
suggest associations with the development of IRIS and specific pathogens. Carriage of 
HLA-A2, -B44 was associated with a history of CMV retinitis and/or encephalomyelitis 
as IRIS, but not with mycobacterial and other infections (45). 
 
Disease specific manifestations of IRIS: 
 
As IRIS is a pleomorphic phenomenon, the epidemiology, clinical features, and treatment 
options for the common infectious manifestations of specific IRIS are reviewed below: 
 
Mycobacterial IRIS: 
Epidemiology: 
The incidence of TB IRIS varies between 37 and 47% in HIV and TB coinfected patients 
initiated on ART (22, 26, 27, 30, 46). In developing countries, TB-IRIS probably 
represents upto one-third of all cases of IRIS (46). The high rates of TB-IRIS may be due 
to persistence of mycobacterial organisms and their cell wall components in host tissues 
for weeks after initiation of anti-mycobacterial treatment. Even non-HIV infected patients 
are well known to have paradoxical reactions in TB lymphadenitis, miliary tuberculosis 
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and CNS tuberculosis (47-51). The high background incidence of paradoxical reactions in 
TB may be another reason for the greater frequency of TB-IRIS(7). 
 
It is unclear whether early initiation of ART following the initiation of TB treatment is a 
risk factor for TB IRIS. While some investigators have found early initiation of HAART 
following initiation of treatment for TB to be a risk factor for IRIS (30, 31), others have 
not found a significant association (26, 28). In most studies, TB-IRIS occurs within two 
months of ART initiation (7). Some other studies have shown that low CD4 count, a good 
immunological and virological response to ART and disseminated TB are also risk 
factors for development of IRIS (7, 26, 30, 31, 46). However, others such as 
Kumaraswamy et al reported no difference between baseline CD4 counts, rise in CD4 
counts and duration between treatment for tuberculosis and HAART between patients 
with and without IRIS (28). 
 
The return of infection specific immunity in the form of tuberculin responses has been 
consistently demonstrated in various studies (23). 
 
In most studies, TB IRIS seems to be most common among patients intitiated on ART 
within the first two months. Several authors have suggested delaying treatment with ART 
until after two months of treatment with anti-tuberculous therapy (ATT). However, in a 
decision analysis on a hypothetical cohort of 1000 patients studying mortality in three 
groups of patients (group 1: ART initiated within first two months of ATT, group 2: ART 
deferred to between 2 and 6 months of ATT and group 3: ART after completion of ATT), 
mortality was the lowest in the group initiated on ART earliest regardless of IRIS. 
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Deferred HAART was favored over early HAART only if the IRIS-related mortality rate 
in the early group exceeded 4.6%. These results support early initiation of HAART in 
patients with AIDS, except when IRIS-related mortality rates are high(52). 
 
One study suggested that median time to onset of IRIS in central nervous system (CNS) 
TB is longer than other sites of TB IRIS (53). 
 
Clinical features: 
The most commonly reported manifestations of M tuberculosis-associated IRIS were 
fever, lymphadenopathy, and worsening respiratory symptoms. In one study, 
lymphadenopathy was the most frequent manifestation, occurring in 71% of the patients 
(54). The second most common manifestation was the development or deterioration of 
parenchymal lung disease as seen in 28% patients. Worsening parynchymal lung 
infiltrates have been commonly reported in various studies on IRIS (7, 28, 30, 46, 55). 
Other miscellaneous manifestations include hepatosplenomegaly, pleural effusion, 
ascites, psoas abscess, splenic abscess, other intra-abdominal abscesses, disease of the 
caecum with or without perforation, epididymo-orchitis, central nervous system lesions, 
skin lesions, ureteric compression, acute renal failure(8), and hypercalcaemia (46, 54) 
 
Treatment: 
Treatment of TB IRIS depends on organs involved and severity. Non-serious 
manifestations respond to initiation of ATT. Steroids have been tried for seriously ill 
patients. Use of steroids has ranged from intravenous methylprednisolone to lower doses 
of oral prednisolone. Steroids have been anecdotally effective but there is lack of 
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controlled trials to demonstrate this. Steroids are indicated in patients with CNS TB. 
Other indications for steroids remain unclear.  
 
Atypical mycobacterial IRIS: 
Epidemiology: 
Atypical mycobacterial IRIS is known to occur with immune reconstitution (1, 2, 56-60). 
It was first described with zidovudine  therapy but has been described in patients on 
protease inhibitor regimens following this(1). Of all atypical mycobacteria (table 1), 
Mycobacterium avium intracellulare appears to be the commonest. Non-TB 
mycobacterial IRIS also seems to be associated with specific reconstitution of CD4 
memory cells which can be demonstrated by immunophenotyping studies of lymph nodes 
(2). 
 
Clinical features: 
MAC associated IRIS has varied manifestations. These include focal lymphadenitis (1, 
23, 57), pyomyositis (56), soft tissue abscesses, acute respiratory distress syndrome 
(ARDS) (59), endobronchial lesions(59), osteomyelitis (59, 60), peritonitis(59), 
intraabdominal abscesses, intestinal obstruction (59) and adrenal masses(59). Most 
patients developed manifestations between 1-8wks(1, 56-59). One study however 
described late non-mycobacterial IRIS in the form of osteomyelitis occurring after more 
than 10 months of ART (60). 
 
 
Treatment 
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Antimycobacterial chemotherapy along with surgical excision of lymph nodes has been 
used in some studies. However, this may result in non-healing sinuses. Needle aspiration 
has also been tried in some cases. In severe cases steroids have been tried with variable 
response.  
 
Hepatitis C 
There are several reports of IRIS related to Hepatitis C infection (HCV). In one study 
involving a retrospective cohort of responders to HAART, three patients had hepatitis of 
which only one had been known to have hepatitis C infection previously. The other two 
seroconverted following initiation of HAART suggesting that the hepatitis resulted from 
the restoration of an immune response against HCV. Subsequent analysis of stored 
plasma showed that HCV RNA had been present even prior to initiation of HAART.  
Both these patients had evidence of chronic hepatitis without eosinophilia or granulomata 
in a liver biopsy indicating that hepatitis was not drug induced (23).  HCV IRIS in this 
study occurred at a mean of 12 weeks after initiation of HAART.  
 
Cutaneous IRIS 
 
a) Dermatomal Zoster 
Incidence of herpes zoster IRIS have varied from 6-40% (13, 22-24, 61). Most patients 
have a CD4 count of less than 50 cells/ml at baseline. This is thought to be a late 
occurring IRIS, sometimes occurring 30 weeks after commencing anti-retroviral therapy 
and almost never occurring in the first four weeks(13).  In one case control study among 
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patients with HIV who developed herpes zoster, being on HAART increased the odds of 
developing herpes zoster by two to five times (62).  Herpes zoster IRIS  may be 
associated with complications including post herpetic neuralgia, infection, ocular and 
neurological complications.  
 
Treatment: 
Treatment with seven days of acyclovir appears to be effective in treatment of herpes 
Zoster IRIS. Addition of steroids to treatment with acyclovir was studied in a randomised 
controlled trial. Addition of steroid decreased healing times, improved acute pain, and 
quality of life, but did not affect the incidence or duration of postherpetic neuralgia (63). 
Sorivudine has been studied in comparison with acyclovir and can be used as an 
alternative(64). Opiods, tricyclic agents and gabapentin can be used for control of post-
herpetic neuralgia. 
 
b) Lepra reactions: 
There are several case reports of reversal reactions described in patients initiated on 
HAART. This may be the first presentation of Hansen’s disease (65-67). The patients are 
usually in the borderline tuberculoid or tuberculoid spectrum. Skin biopsy typically 
shows well formed granulomas. This is usually associated with a rise in CD4 counts. 
Time of occurrence is usually between one and six months after initiation of HAART 
(65). The lepromin test may or may not be positive. Type 1 reactions are usually 
associated with increase in cellular immunity and are not very common in patients with 
HIV infection. Reactional leprosy type 1 can be considered a marker of IRIS in HIV-
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infected patients who are receiving HAART. Treatment for IRIS presenting as a lepra 
reaction is the same as for type I reaction in Hansen’s disease.  
 
c) Molluscum Contagiosum 
There are several case reports of patients developing molluscum contagiosum as IRIS 
(23, 26). In one study, 9% (4/44) of patients developed molluscum contagiosum 
following initiation of HAART. The median time to development of IRIS was 8 
weeks(24).  
 
Cryptococcal meningitis 
The incidence of IRIS in patients with HIV and crypococcal meningitis newly initiated 
on ART was reported to be 30% in one cohort study (68).  
 
Clinical features: 
Various manifestations of cryptococcosis as an IRIS have been described in patients 
initiated on ART including cryptococcal meningitis, raised intra-cranial pressure, 
intrathoracic lymphadenopathy, hypercalcemia, cavitatory pneumonia(15, 36), ARDS 
(36) and supraclavicular abscess(15). IRIS usually occurs within the first two months (14, 
36, 69, 70) although some studies indicate that it can occur as late as 11 months after 
initiation of ART(15). Although cryptococcal infection in HIV may be characterised by a 
low grade inflammatory response causing only mild CSF leukocytosis, in IRIS it is 
usually associated with a marked inflammatory cellular response with negative smears 
and cultures (36, 69). Since relapse is common in treated cryptococcal meningitis, it is 
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important to distinguish this from immune reconstitution (70). In one study, high antigen 
titres in CSF and early initiation of ART following treatment for cryptococcal meningitis 
(<30days) were found to be risk factors for IRIS (68). C. neoformans-related IRIS 
patients also had higher baseline plasma HIV RNA levels and higher CSF cryptococcal 
antigen titers, opening pressures, WBC counts, and glucose levels (68, 71). 
 
Treatment: 
Amphotericin and flucytosine combinations are associated with the fastest clearance of 
infection in cryptococcal meningitis (72). In severe IRIS, steroids have been used and 
have been found to be useful in case reports (36, 73). Hydroxychloroquine has also been 
used in some cases for its anti-inflammatory activity (73) 
 
CMV IRIS: 
CMV IRIS was described when CMV retinitis was noticed to occur in patients on 
HAART with CD4 counts that were much higher than expected. This was noticed to 
occur 4-7weeks after initiation of HAART  (10). In a retrospective cohort, CMV-related 
IRIS was common (6/33 of IRIS cases, or 18%) (23). A new syndrome of immune 
recovery vitritis (IRV) was described as a syndrome of posterior segment intraocular 
inflammation that causes visual loss in patients with AIDS and CMV retinitis. On 
analysis of data from the pre-HAART era, this syndrome was noted to occur only in 
patients on HAART who had CMV retinitis in the past. It was associated with marked 
inflammation, visual impairment and higher CD4 counts (74).  Immune recovery uveitis 
presents presents as vitritis, macular edema, or formation of epiretinal membrane and can 
severely compromise vision. This is thought to be an inflammatory response to persisting 
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CMV antigen and not due to the replication of the virus. In one study, PCR for CMV  
from aqueous humor was negative in all patients with IRV and they had high levels of IL-
12 and low levels of IL-6 and interferon gamma (suggestive of an antigen specific 
response) (75). The incidence of IRV varies between 17.6% to 63% among patients with 
previous CMV retinitis in different studies (76, 77). In one study, the median time to 
development of IRV was 43 weeks (76). Male gender, use of ART, higher CD4 cell 
counts, and involvement of the posterior retinal pole are associated with a reduced risk of 
developing IRV, whereas prior use of intravitreous injections of cidofovir, large retinal 
lesions, and adequate immune recovery on ART are associated with increased risk of IRV 
(77). 
 
Treatment: 
Treatment of IRIS associated CMV retinitis and IRV may involve anti-CMV therapy 
with gancyclovir or valgancyclovir(78). However, the usefulness of this is debatable 
since immune recovery vitritis is not considered an infective complication as evidenced 
by negative CMV DNA tests in all these patients. Furthermore, ongoing treatment of 
healed CMV retinitis after immune recovery does not appear to protect against the 
development of immune recovery uveitis (79). In fact cidofovir use has been associated 
with a higher incidence of immune recovery uveitis (79). The use of systemic 
corticosteroids has been successful, and IRV may require periocular corticosteroid 
injections (80-82). 
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Methodology 
 
Type of study 
Prospective cohort study of HIV infected patients initiated on HAART at our hospital or 
referred to ART centres between 1st November 2006 and 1st November 2007. 
 
Sample size 
With an expected incidence of 25% and absolute precision of 8% with an alpha error of 
5% and expected loss to follow up taken as 20%, the desired sample size to calculate 
incidence is 142.  
 
Methods 
All patients initiated on HAART or referred for HAART to ART centres, on follow up at 
our hospital between 1st November 2006 and 1st November 2007 were recruited. Patients 
had baseline CD4 lymphocyte counts tested prior to initiation of HAART. A complete 
physical examination of every patient was done at baseline. Clinical and laboratory 
characteristics, age, WHO staging of HIV infection, body mass index (BMI), previous 
opportunistic infections, CD4 lymphocyte counts and absolute lymphocyte counts (ALC) 
were recorded. Patients were monitored for development of new symptoms or 
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opportunistic infections for a period of six months. Patients who did not return to the 
clinic on follow up dates were contacted by phone and mail. Any new symptoms were 
recorded and a physical examination was carried out at every visit. 
The following definitions were used to diagnose IRIS and IRIS like syndrome: 
 
Definition of typical IRIS (Immune reconstitution inflammatory syndrome) 
Typical IRIS meets the following criteria 
• HIV infected person receiving HAART deteriorating following initiation of 
HAART 
• Immune reconstitution evidenced by 
            Decrease in HIV-1 RNA levels from baseline or 
            Increase in CD4 counts from baseline 
• Clinical symptoms, signs or laboratory investigations consistent with an 
inflammatory process  
• Clinical course not consistent with 
1. Expected course of previously diagnosed OI or  expected course of 
newly diagnosed OI 
2. Drug toxicity 
 
Definition of IRIS like syndrome 
• Onset of new OI after initiation of HAART 
• Worsening of old OI after initiation of HAART 
• Worsening not due to drug toxicity or irregular treatment for previous OI 
• On treatment with regular HAART 
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Incidence of IRIS was calculated in the cohort using the above definitions. Incidence 
rates of IRIS among patients with pre-existing opportunistic infections receiving 
HAART were calculated for each opportunistic infection.   
 
Patients with any new clinical symptoms underwent physical examination and CD4 
lymphocyte counts were enumerated. Clinical symptoms, signs, relevant 
investigations, CD4 lymphocyte counts, time from previous opportunistic infection, 
treatment and outcomes were recorded in detail. Type of OI associated with IRIS was 
determined according to criteria described below. Baseline characteristics of patients 
who developed IRIS were compared with those of patients who did not, and 
predictive factors were identified.  
 
Definitions of specific IRIS: 
 
Mycobacterial IRIS: 
 
TB lymphadenitis associated IRIS:   
Enlarging lymph nodes following initiation of HAART in patients known to have 
previous tuberculous lymphadenitis (confirmed by  previous smear or culture)  or 
enlarging lymph nodes following intiation of HAART with smear or culture positivity 
among patients with no previous diagnosis of TB lymphadenitis. 
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Pulmonary tuberculosis associated IRIS:  
Appearance of fever with, or without cough and breathlessness, with, or without chest 
infiltrates following initiation of HAART in patients known to have tuberculosis (or)  
appearance of fever with or without cough, breathlessness and chest infiltrates in 
patients not known to have TB, confirmed by sputum acid fast bacilli (AFB) smear 
positivity or culture positivity 
 
Disseminated tuberculosis 
Appearance of fever with or without hepatosplenomegaly and lymphadenopathy with 
isolation of AFB on smear or culture from bone marrow, lymph node , liver biopsy or 
cerebrospinal fluid (CSF) or histopathological confirmation by granuloma formation 
in bone marrow or liver. 
 
Tuberculous meningitis 
Appearance or worsening of symptoms of fever and headache with or without altered 
sensorium and neck rigidity with elevated protein and cellular response in CSF with 
lymphocytic predominance, cultures and smear for cryptococcus being negative, with 
or without CSF AFB smear or culture isolation with response to treatment with ATT 
and steroids.  
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Cryptococcal IRIS 
 
Cryptococcal meningitis associated IRIS 
Appearance or worsening of fever and headache with or without altered sensorium 
and neck rigidity with CSF positive for cryptococcus India ink, cryptococcal antigen 
or cryptococcal culture. 
    
Pneumocystis jirovecii associated IRIS 
Worsening breathlessness, fever and hypoxemia with bilateral interstitial lung 
infiltrates or nodular shadows following initiation of HAART which improves on 
treatment with HAART and cotrimoxazole or sputum positive for Pneumocystis 
jirovecci by fluorescent antibody or silver staining.  
          
      Cytomegalovirus (CMV)  associated IRIS 
Blindness or diminished vision with fundoscopic appearance suggestive of CMV 
retinitis or features suggestive of CMV vitritis or uveitis. Features of gastrointestinal 
involvement with confirmation by histopathology or virology to suggest CMV colitis 
or oesophagitis. 
 
 
 
Progressive multifocal leukoencephalopathy (PMLE) IRIS 
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Appearance of focal neurological deficits with imaging suggestive of white matter 
inflammation. 
 
Toxoplasma IRIS 
Appearance of focal neurological deficits with imaging showing a ring enhancing 
lesion with response to treatment for toxoplasmosis alone.  
 
Hansen’s disease IRIS 
Swelling, erythema or tenderness of patches in patients with leprosy or neuritis 
suggesting a type I lepra reaction. 
 
 
Statistical analysis: 
 
Means of continuous variables were compared using the independent sample T test 
among patients who did and did not develop IRIS. Discrete variables were compared 
using chi square test. Analysis was done with SPSS version 11.  
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Results 
A total of 141 patients were evaluated for initiation of HAART between 1st November 
2006 and 30th October 2007 (Figure 1). Of these, 109 were initiated on HAART (67 at 
Christian Medical College and 42 at different other ART centres including four centres in 
Tamil Nadu and three centres in Andhra Pradesh). These 109 patients were followed up 
for a total of 62 person-years and a mean duration of 207 days. For 19 patients (17%) the 
follow-up was less than six months ranging between 14 and 136 days. Ten of these 
patients were followed up at CMC and 9 were followed up at government-run ART 
centres. Of the 90 patients who completed six-months follow-up, 75 (83%) patients were 
followed up in person at the Infectious Disease Clinic at CMC and the remainder through 
phone and mail. 
Figure 1. Patient recruitment for study  
141 patients evaluated 
for initiation of ART 
(67 at CMC, 74 at GH*)
109 patients enrolled
(67 at CMC, 42 at GH*)
32 patients excluded
•28 did not follow up after
referral to ART centre
•3 patients- ART deferred
90 patients
complete 
follow up
(>6 months)
19 patients
Incomplete
follow up
(< 6 months)
 
 
*GH Government hospital ART centres 
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Table 5. Baseline characteristics of patients 
 
D4T : Stavudine 
3TC : Lamivudine 
ZDV: Zidovudine 
NVP: Nevirapine 
EFV: Efavirenz 
TDF: Tenofovir 
EMT: Emtricitabine 
 
 
Baseline characteristics All patients n=109 
 
Sex 
     Male 
     Female 
Age (mean in yrs) 
BMI (mean) 
BMI subgroups [%] (n=101) 
      <18 
       18-25 
       >25 
WHO stage 
      I 
      II 
      III 
      IV  
 Mean CD4 counts (cells/ml) 
CD4 count subgroups 
      <50 
      50-100 
      100-150 
       150-200 
       >200 
 
Mean Absolute lymphocyte count(/ul) 
HAART regimens (n=101) 
      D4T+3TC+NVP 
      ZDV+3TC+NVP 
      D4T+3TC+EFV 
      D4T+3TC+EFV 
      EMT+TDF+EFV 
 
 
72 (66%) 
37 (34%) 
            38 (range 23-76) 
             21 (range 11-28) 
 
28(28%) 
57(57%) 
16(15%) 
 
37 (34%) 
8(7%) 
19(18%) 
45 (41%) 
131 (range 7-346) 
 
18(17%) 
24(23%) 
18(17%) 
23(22%) 
21(20%) 
 
1358 (range 44-4459) 
 
36(37%) 
32(33%) 
17(17%) 
8(8%) 
5(5%) 
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Table 6: Previous opportunistic infections in cohort (n=109) 
 
 
 
 
PRESENCE OF PRIOR OPPORTUNISTIC INFECTION  
Previous Opportunistic Infections (OIs) Entire group   
No.(%) n=109 
Presence of prior opportunistic infections 49(45%) 
Absence of prior opportunistic infection  60(55%) 
 
INDIVIDUAL  OPPORTUNISTIC INFECTIONS  
TB (all) 40(35%) 
Pulmonary TB 
TB lymphadenitis 
Pleural effusion 
Pericardial effusion 
Disseminated TB 
TB Meningitis 
Bone TB 
5 
13 
2 
1 
15 
2 
2 
Cryptococcal meningitis 0(0%) 
Pneumocystis Pneumonia (PCP) 2(2%) 
Cytomegalovirus Infection (CMV) 2(2%) 
Herpes zoster 2(2%) 
Candidal esophagitis 2(2%) 
Chronic diarrhea 2(2%) 
 40
Baseline characteristics: 
The baseline characteristics of the patients are presented in Table 5 (on opposite sheet).  
Of all patients, 66% of patients were male and 59% of the patients were in WHO stage III 
and IV HIV infection at the time of enrollment. BMI was less than 18 in 28% of patients. 
Mean CD4 lymphocyte count was 131 cells/ml and 79% patients had CD4 lymphocyte 
counts below 200 cells/ml, indicating that the majority of patients had AIDS. Of all 
patients, 68% were on treatment with nevirapine-based regimens (Table 5). The 
remaining patients were on various combinations of efavirenz-based regimens. None of 
the patients were on protease inhibitors.  
 
Among the patients, 45% had a previous OI, the commonest being TB (40 of 49 patients). 
Of these 40 patients with TB, 15 (37.5%) had disseminated tuberculosis, 13 (33%) had 
previous tuberculous lymphadenitis, 2 (5%) had pleural tuberculosis, 2 (5%) had TB 
meningitis and 2 (5%) had TB osteomyelitis. Only one patient had previous pericardial 
TB. Two patients had previous Pneumocystis pneumonia (PCP), Cytomegalovirus 
(CMV) retinitis, herpes zoster and esophageal candidiasis. There were no patients with 
cryptococcal meningitis in the cohort. The details of previous opportunistic infections in 
the study group are presented in table 6 (on opposite sheet). 
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Table 7: Overall incidence of IRIS and opportunistic infection specific IRIS incidences: 
Type of IRIS No. Incidence Confidence limits 
All IRIS 14 12.8% (7.2%, 20.6%) 
Tuberculous IRIS 9 8% (3.8%,15.1%) 
CMV IRIS* 2 1.8% (0.2%, 6.5%) 
Cryptococcal IRIS 1 1% (0.02%,6.4%) 
PMLE** 1 1% (0.02%,6.4%) 
Herpes Zoster 1 1% (0.02%,6.4%) 
 
*Cytomegalovirus immune reconstitution inflammatory syndrome 
**Progressive multifocal leukoencephalopathy 
 
Figure 2: Cumulative frequency of IRIS by time 
1 2 3 4 5 60
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20
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40
50
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80
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Frequency
Of IRIS
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n=12
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n=14 n=14 n=14
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Incidence of IRIS: 
A total of 14 patients developed IRIS out of 109 patients, with an incidence of 12.8% (CI 
7.2%, 20.6%). Cumulative incidence was 22 per 100 person-years. Cumulative incidence 
in the first two months after initiation of HAART was 11.4% (12 of 109 patients). 
Incidence of IRIS after first two months was only 1.4% (2 of 109 patients) (see Figure 2). 
Among various types of opportunistic infections presenting as IRIS, TB IRIS was the 
commonest with an incidence of 8% (CI 3.8%, 15.1%). The incidence of disease specific 
IRIS is outlined in Table 7: 
 
The frequency of TB IRIS among patients with patients with prior TB was 12.5% (4.2%, 
26.8%). The same frequency could not be calculated for other opportunistic infections 
because of the small numbers.  
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Table 8: Profile of IRIS 
Type of IRIS No
. 
Prior 
infection 
with 
same OI 
Mean 
CD4 at 
time of 
initiation 
of 
HAART(/
ul) 
Mean 
CD4 at 
time of 
IRIS(/ul) 
Mean 
time to 
IRIS 
(days) 
Management Outcome 
All TB IRIS 9 5 123 419 43 ATT* Improved 
Types of TB  
Disseminated 
Lymph node 
CNS 
Skin 
Pulm TB 
 
1 
3 
2 
1 
2 
  
134 
162 
140 
154 
161 
 
272 
418 
818 
418 
162 
 
35 
79 
14 
30 
5 
 
ATT 
ATT 
ATT+st** 
ATT 
ATT 
 
Improved 
Improved 
Improved 
Improved 
Improved 
All CMV IRIS 2 0 24 146 27 Gancyclovir Improved 
Individual 
CMV infection 
CMV Retinitis 
CMV 
Esophagitis 
 
 
1 
1 
  
 
7 
42 
 
 
161 
131 
 
 
39 
15 
-  
 
Improved 
Improved 
Herpes zoster 1 0 177 626 27 Acyclovir Improved 
Cryptococcal 
meningitis 
1 0 119 NA 7 Amphotericin Expired 
PMLE 1 0 116 151 4 - Improved 
Total (All 
IRIS) 
14 5 121 332 33   
*ATT : Anti-tuberculous treatment 
**st: Steroids 
 
Table 9: Magnitude of rise in CD4 lymphocyte counts in patients with IRIS 
 
Magnitude of rise in CD4 lymphocyte counts No.  total n=12 
< 100 cells/ml 4 
100 – 200 cells/ml 3 
200 – 400 cells/ml 3 
>400 cells/ml 2 
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Profile of IRIS patients: 
Overall profile of IRIS 
The profile of IRIS patients is described in table 8.  
There were 14 cases of typical IRIS and 3 cases of IRIS like syndrome. The three cases 
of IRIS like syndrome were not included in the final analysis. Of the cases of IRIS, there 
were 9 cases of TB IRIS, 2 CMV IRIS, 1 herpes zoster IRIS, 1 cryptococcal meningitis 
IRIS and 1 PMLE IRIS. Thirteen of 14 patients presented with AIDS defining illnesses. 
There were no cases of Pneumocystis jirovecii or atypical mycobacterial IRIS. Only 5 of 
the fourteen cases had a prior opportunistic infection, all in the TB IRIS group. The 
mean CD4 at the time of initiation of ART was 121 cells/ml and only 2 patients had a 
baseline CD4 count of more than 200 cells/ml. The mean CD4 lymphocyte count at the 
time of development of IRIS was 332 cells/ml. All patients had an increase in CD4 
lymphocyte count, but the degree of increase was variable from less than 100 cells/ml to 
more than 400 cells/ml (Table 9). The time to development of IRIS following initiation 
of HAART was variable (4-120 days) with a mean of 33 days. 85% of patients 
developed IRIS within two months of initiation of HAART. None of the patients had 
more than one opportunistic infection presenting as IRIS. There was a variable rise in 
CD4 counts in cases of IRIS (Table 9). 
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Table 10: Proportion of patients who fit specific definition criteria for IRIS: 
Defainition criteria for IRIS Proportion of patients 
fitting criteria no.(%) 
• HIV positive receiving HAART developing 
deterioration following initiation of HAART 
 
14(100%) 
• Immune reconstitution evidenced by 
            Decrease in HIV-1 RNA levels from baseline or 
            Increase in CD4 counts from baseline 
 
12(85%) 
• Clinical symptoms, signs or investigations consistent 
with an inflammatory process  
 
14(100%) 
• Clinical course not consistent with 
• Expected course of previously diagnosed OI or    
expected course of newly diagnosed OI 
• Drug toxicity 
 
13(92%) 
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Of the 14 patients, all cases fulfilled criteria of deterioration following initiation of 
HAART and clinical profile suggestive of an inflammatory process (Table 9). Twelve 
patients had evidence of immune reconstitution and 13 had a clinical course not 
consistent with previous or newly diagnosed opportunistic infections. The proportion of 
patients that satisfied individual criteria for IRIS are shown in table 9. 
 
All patients were treated for underlying opportunistic infections and two required 
treatment with steroids. All cases improved on treatment of OI, except one, who expired 
due to drug toxicity (case M, Appendix). HAART was not withdrawn for any patient.  
 
Profile of TB IRIS (see appendix for individual case descriptions- cases A to I) 
The most common opportunistic infection manifesting as IRIS was tuberculosis in 64% 
of cases. Of 9 patients with tuberculosis, 3 presented with TB lymphadenitis, 2 with  TB 
meningitis, 2 with pulmonary TB, 1 with a tuberculous ulcer over the right thigh and one 
with disseminated tuberculosis. Only five of the patients had evidence of prior TB. The 
time to development of TB IRIS following initiation of HAART varied from 5 days to 
120 days. Two patients who went on to develop IRIS had been suspected to have 
tuberculosis prior to initiation of HAART but were not treated. In one of these patients, 
the diagnosis could not be confirmed and in another empirical anti-tuberculous therapy 
was discontinued due to drug rash. The clinical severity of TB IRIS varied from 
localized lymph nodal involvement to severe disseminated involvement with high fever, 
pulmonary, disseminated lymph node and hepatic involvement. In two cases the site of 
TB IRIS involvement was not the initial site of TB involvement. Five of 9 patients  
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had acute presentations (<2weeks). TB IRIS occurred in all groups irrespective of time 
of initiation of HAART in relation to TB treatment; 2 cases initiated on HAART within 
2 months of TB treatment and 3 cases after completion of TB treatment.  
 
All patients who presented with localised TB lymphadenitis had involvement of only 
one group of lymph nodes with demonstration of granulomatous inflammation on fine 
needle aspiration cytology. Both patients with CNS tuberculosis presented with 
paradoxical worsening after initial improvement on anti-tuberculous treatment and 
demonstrated cellular response in CSF. Both patients with pulmonary involvement 
presented acutely with lower zone involvement and sputum AFB positivity. The patient 
with skin involvement presented with ulcerated lesion of the thigh. Four patients had 
multi-organ involvement at the time of presentation. These patients had combinations of 
pulmonary, hepatic, CNS and lymph node involvement. Of these, three patients had 
marked alkaline phosphatase elevation and in one, granulomatous inflammation was 
demonstrated on liver biopsy.   
 
All patients improved on treatment for tuberculosis. Both patients with CNS tuberculosis 
were also treated with steroids. 
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Profile of CMV IRIS (see appendix for individual case descriptions- cases J and K) 
There were two patients who developed CMV related IRIS. One patient presented with 
retinal involvement and the other with oesophageal and retinal involvement. Their 
baseline CD4 counts were 7 cells/ml and 42 cells/ml respectively.  Neither of these 
patients had previously detected CMV. The time to development of IRIS was 11 days 
and 14 days in case J and K respectively. CD4 counts rose by 154 and 89 cells/ml in case 
J and K respectively. 
 
Case K developed worsening dysphagia and choking following intitiation of HAART 
and was found to have oesophageal ulceration with a tracheo-oesophageal fistula. 
Fundus examination showed peripheral CMV retinitis and peripheral blood CMV PCR 
was positive. Although CMV oesophagitis could not be confirmed on the oesophageal 
biopsy), CMV was the most likely etiology in view of concurrently occurring CMV 
retinitis. The second patient developed CMV retinitis with loss of vision following 
initiation of HAART with partial improvement on treatment with gancyclovir.  
 
Herpes Zoster IRIS (see appendix for individual case description- case L) 
One patient developed localized dermatomal herpes zoster accompanied by severe pain 
27 days after initiating HAART. His CD4 count rose to 626 cells/ml from 177 cells/ml at 
baseline. He improved on treatment with acyclovir and did not develop post herpetic 
neuralgia subsequently.  
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Crytpococcal meningitis IRIS (see appendix for case descriptions- case M) 
One patient presented with cryptococcal meningitis three months following initiation of 
HAART. His baseline CD4 count was 119 cells/ml. He had acute deterioration with a 
cellular response in CSF and india ink positivity consistent with a diagnosis of 
cryptococcal IRIS. He had not been diagnosed to have cryptococcal meningitis prior to 
this. He developed severe refractory hypokalemia and acute renal failure within a week 
of initiating amphotericin. The possible cause of death in this patient is drug related 
toxicity.  
 
PML IRIS (see appendix for case description- case N) 
One patient developed PML related IRIS. This patient presented with acutely worsening 
cerebellar symptoms in the form of dysarthria and ataxia 3 days following initiation of 
HAART. His CD4 counts demonstrated a rise from 116 cells/ml at baseline to 151 
cells/ml at time of IRIS. MRI brain demonstrated  cerebellar demyelination consistent 
with a diagnosis of PML. His condition improved markedly, without treatment with 
steroids.  
 
 
Individual case presentations are described in detail in the appendix. 
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Table 11: Baseline characteristics of 106 patients with and without IRIS (3 patients with 
IRIS like syndrome excluded) 
 
 
 
 
 
 
 
 
 
 
 
Baseline characteristics 
Patients with 
IRIS 
Patients without 
IRIS 
P value 
Total number 
Sex 
     Male 
     Female 
Age (mean in yrs) 
BMI (mean) 
BMI subgroups [%] (n=101) 
      <18 
       18-25 
       >25 
WHO stage 
      I 
      II 
      III 
      IV  
 Mean CD4 counts (cells/ml) 
CD4 count subgroups 
      <50 
      50-100 
      100-150 
       150-200 
       >200 
 
Mean Absolute lymphocyte 
count(cells/ml) 
HAART regimens (n=98) 
      D4T+3TC+NVP 
      ZDV+3TC+NVP 
      D4T+3TC+EFV 
      D4T+3TC+EFV 
      TDV+EMT+EFV 
 
14 
 
10(71%) 
4(29%) 
41 
20 
 
7(50%) 
5(35%) 
2(14%) 
 
4(28%) 
0(0) 
2(14%) 
8(57%) 
121 
 
4(29%) 
1(7%) 
2(14%) 
5(36%) 
2(14%) 
 
1170 
 
 
5(35%) 
4(29%) 
1(7%) 
0(0%) 
4(29%) 
 
88 
 
60(66%) 
32(34%) 
38 
21 
 
21(24%) 
52(59%) 
14(16%) 
 
33(36%) 
8(8%) 
15(16%) 
36(39%) 
134 
 
14(16%) 
23(25%) 
16(18%) 
18(20%) 
19(21%) 
 
1398 
 
 
31(37%) 
28(33%) 
16(19%) 
8(10%) 
1(1%) 
 
 
0.65 
 
0.27 
0.24 
 
0.12 
 
 
 
0.20 
 
 
 
0.59 
 
0.32 
 
 
 
 
 
0.34 
 
 
NA 
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 Predictive factors for IRIS: 
The baseline characteristics and previous opportunistic infections among patients with 
and without IRIS are outlined in Tables 10 and 11. 
Baseline characteristics were compared among patients with and without IRIS. There 
were no significant differences in age, gender, baseline CD4 counts, absolute lymphocyte 
counts or mean body mass index (BMI) between the patients who developed IRIS and 
those who did not (Table 6). Among patients with CD4 counts below 200 cells/ml, 15% 
developed IRIS as compared to 10% among patients with higher CD4 counts (p=0.55).  
 
Mean BMI was similar among patients with and without IRIS. 25% of the patients with a 
BMI of less than 18 developed IRIS compared to 12.5% of patients with a BMI of more 
than 25, although this difference was not significant (p=0.124). 
 
The incidence of IRIS in patients with early stages of HIV infection (WHO stage I and II) 
was 8.9% compared to 16.4% in patients with late stages of HIV infection (WHO stages 
III and IV), although this difference was not statistically significant (p=0.25). 
 
 Patients with early and late stages of HIV infection developed similar types of IRIS, 
although CMV infections were more common in WHO Stage III and IV disease. The 
mean time to development of IRIS was similar in early and late stages of HIV infection. 
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Table 12: Previous opportunistic infections among patients with and without IRIS 
 
*3 patients with doubtful IRIS excluded 
 
 
 
Previous OIs IRIS* No IRIS* P value 
No prior OI 5(36%) 55(60%) 0.09 
Prior OI 9(64%) 37(40%) 0.09 
TB (any) 7(50%) 30(33%) 0.20 
Pulm TB 
Lymphadenitis 
Pleural 
Pericardial 
Disseminated 
TB Meningitis 
Bone 
2(29%) 
1(14%) 
0(0%) 
0(0%) 
2(29%) 
2(29%) 
0(0%) 
2(7%) 
10(33%) 
2(7%) 
1(3%) 
13(43%) 
0(0%) 
2(7%) 
NA 
Cryptococcal 
meningitis 
0(0%) 0(0%) NA 
PCP 1(7%) 1(1%) NA 
CMV 0(0%) 2(2%) NA 
Herpes zoster 0(0%) 2(2%) NA 
Candidal 
esophagitis 
2(14%) 0(0%) NA 
Chronic diarrhea 0(0%) 2(2%) NA 
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There was no significant difference between incidence of IRIS among patients who 
received efavirenz and nevirapine based regiments (19% and 12% respectively, p=0.32). 
However, among patients being treated with emtricitabine, tenofovir and efavirenz, four 
out of five patients (80%) developed IRIS. The mean rise in CD4 lymphocyte count from 
baseline was 375 cells/ml (range, 1 to 980 cells/ml). Since these numbers are small, it is 
difficult to comment upon their significance. 
 
Out of the 14 patients who developed IRIS, 9 patients had been previously diagnosed to 
have an opportunistic infection. Of these 9 patients, only 5 patients developed 
manifestations of an opportunistic infection similar to their previous opportunistic 
infection. The incidence of IRIS was higher among patients with previous opportunistic 
infections although this difference did not attain statistical significance (19.6% among 
patients with previous opportunistic infections compared to 8.3% among those without 
previous OIs, p value=0.09). Among patients with previously diagnosed tuberculosis 
19% developed IRIS as compared to 10% among patients without previously diagnosed 
tuberculosis (p=0.20).  Disseminated tuberculosis was not found to be a significant 
predictive factor for development of IRIS (p=0.57). 
 
Early initiation of HAART after diagnosis of opportunistic infection (less than two 
months) was not found to be a significant predictive factor for IRIS.  Among patients 
with tuberculosis 17% of patients initiated on HAART within two months and 27% of 
patients initiated on HAART more than six months after initiation of ATT developed 
IRIS. These differences were not statistically significant.  
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Multivariate analysis could not be done in relation to the baseline characteristics and 
previous opportunistic infections due to the low rate of events and lack of significant 
predictive factors for IRIS on univariate analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
      54 
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Discussion 
 
This study has shown that IRIS is a significant problem in patients started on HAART in 
India. The calculated incidence of IRIS in the cohort studied was 12.8% (14/109 
patients). This is the only prospective study that has studied the overall incidence of IRIS. 
The overall IRIS rate reported in this study at 12.8% was lower than that reported in other 
studies of 25%, 16.7% and 22% (22-24).  The reasons for lower rates of IRIS in our study 
may be the following: 
 
1. A smaller proportion of patients with very low CD4 counts in this study: French 
et al studied a cohort in which 58% of patients had a CD4 count less than 50 
cells/ml as opposed to 17% of patients in our cohort suggesting that the patients in 
the aforementioned group may have had more advanced disease(23). In another 
study, 61% of patients had CD4 counts below 100 cells/ml(22). 
2. The prospective design of this study: Most other studies that reported IRIS rates 
were retrospective studies that may have over-represented event rates(22-24). 
3. Lower rates of dermatological IRIS: In other studies(22-24) the proportion of 
dermatological IRIS varied from 43 to 78% compared to 7% in our study. The 
low rates of dermatological IRIS may reflect under-reporting of skin lesions 
among patients in this study. 
4. Lack of use of protease inhibitor (PI) based regimens in this study: Jevtovic et al 
reported use of PI based regimens in 64% of patients compared to no patients in 
this study(22).  
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The variable rates of IRIS in different studies is probably a reflection of the 
following: 
a. The heterogeneous nature of the syndrome  due to a variety of opportunistic 
infections 
b. The complex interplay between antigen burden, immune response and underlying 
genetic factors that underlie the pathophysiology of the syndrome. 
c. Multiple factors may determine the occurrence of IRIS such as the background 
opportunistic infections, severity of immunodeficiency, type of ART and timing 
of ART. 
For all these reasons IRIS may not occur at a predictable rate. 
 
There was a variable rise in CD4 lymphocyte count among patients in this study. Grabar 
et al. showed that CD4 mean increase during the first 6 months on HAART was 42.9 
cells/ml per month in patients under 50 years and 36.9 cells/ml per month in patients over 
50 years of age(83). The rise of CD4 in some of our patients far exceeded this anticipated 
rise in the given time period. Among studies on patients with IRIS, higher increments in 
CD4 count have been reported. French et al. reported median increase of 97 and 66 
cells/ml among patients with and without IRIS at six weeks following initiation of IRIS 
(23).  Breton et al. also described an increment in CD4 count of 99 cells/ml in patients 
with IRIS in comparison to 35 cells/ml in patients without IRIS at one month following 
inititation of HAART (30). The mean rise in CD4 count at time of IRIS from baseline in 
this study was 111 cells/ml, which is consistent with the data in the studies described 
above.  
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The majority of patient with IRIS in this study had not been previously diagnosed to have 
the same OI that caused the IRIS. In this study 5 patients with IRIS had previously been 
diagnosed to have the same opportunistic infection that caused the IRIS, in 4 cases the OI 
was different from the one diagnosed previously and in 5 cases OI had not been 
diagnosed previously. In all the cases where IRIS was due to the previously diagnosed 
OI, the underlying opportunistic infection was TB. This observation is consistent with 
report by Ratnam et al. that only 10 patients out of 44 patients who developed IRIS had 
prior opportunistic infections (24). All four patients with TB IRIS in this study had been 
treated for tuberculosis prior to initiation of HAART.  Most studies on IRIS have not 
reported on occurrence of previous OIs.  
 
The spectrum of opportunistic infections in this study was different from other cohorts in 
the following respects: (a) the rank order of the OIs causing IRIS in this study was TB 
(65%), CMV (14%), Cryptococcus (7%), PMLE (7%) and Herpes zoster (7%) in contrast 
to the study by Jevtovic et al where the rank order was dermatomal IRIS (51%) , 
Hepatitis C (23%), TB (12%), Hepatitis B (5%), CMV (5%), toxoplasma (2%), PML 
(2%) (see Figure 3); (b) TB was the cause of two-thirds of IRIS; (c) there were fewer 
patients with dermatological IRIS;  (d) there were no patients with atypical mycobacterial 
IRIS, Hepatitis B and C related IRIS, Kaposi’s sarcoma, toxoplasmosis and Pneumocystis 
jirovecii infection in our cohort. The lack of atypical mycobacteriosis IRIS may reflect 
the low background incidence of this infection in our cohort. Low rates of PCP and 
toxoplasmosis may be due to low background rates due to widespread use of 
cotrimoxazole prophylaxis. Low rates of Hepatitis B and C IRIS may reflect low 
background rates of HIV- Hepatitis B and C co-infection (the cohort had only one patient 
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with hepatitis B and no patients with HCV infection). The infrequent occurrence of  
Hepatitis B and C co-infection may reflect virtual absence of history of IV drug use 
among HIV patients presenting to our clinic. Other IRIS syndromes reported in the 
literature but not documented in our study were molluscum contagiosum, genital herpes 
simplex, tinea corporis, genital warts, cerebral toxoplasmosis and, Kaposi’s sarcoma (22). 
This study suggests that the spectrum of IRIS is dependent on the background prevalence 
of opportunistic infections in the specific setting. In India in contrast to western settings 
IRIS is chiefly due to tuberculosis. 
 
Figure 3. Spectrum of IRIS in our study in comparison with Jevtovic et al. 
51%
12%
2%
2%
5%
5%
23%
Dermatomal IRIS Tuberculous IRIS Toxoplasma IRIS PML IRIS
CMV IRIS Hepatitis B IRIS Hepatitis C IRIS
Jevtovic et al.
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Study Cohort
7%
65%
7%
7%
14%
Dermatomal IRIS Tuberculous IRIS Cryptococcal IRIS
PML IRIS CMV IRIS
 
 
  
The frequency of TB IRIS in our study probably reflects the high burden of TB infection 
and disease in patients with HIV infection in our population. The overall incidence of TB 
IRIS in our cohort was 8%. The rates of TB IRIS have been variable between different 
studies. In retrospective cohort studies of patients initiated on HAART(22-24), the 
overall incidence of TB IRIS was low ranging between 0.8% and 2%. This may reflect 
the low background prevalence of tuberculosis in the population studied. There are other 
prospective studies on patients with HIV and TB co-infection which showed higher 
incidences of TB IRIS ranging between 15% and 37%(7, 27, 29). However, baseline CD4 
counts were lower in these studies suggesting that these may have been groups with more 
advanced disease. In this study, 12% of patients with HIV-TB co-infection developed 
IRIS. This is almost twice the incidence reported by Kumaraswamy in Chennai of 7.6% 
(11/144) in patients with TB-HIV co-infection (28). 
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The following clinical observations can be made with regards to TB IRIS from this study: 
a. Clinical presentations of TB IRIS were similar to descriptions from previous 
studies. The clinical presentations included tuberculous lymphadenitis, CNS TB, 
pulmonary tuberculosis, disseminated TB and skin TB. 
b. Most patients presenting with TB-IRIS did not have previously diagnosed 
tuberculosis. 
c. Clinical severity of TB-IRIS varied from transient lymphadenitis to severe CNS 
TB.  
d. A high index of suspicion is necessary for the diagnosis of TB prior to initiation 
of HAART. In two patients who developed TB-IRIS, TB had been suspected prior 
to initiation of HAART but could not be confirmed.  
e. Multi-organ involvement is common reflecting disseminated involvement of 
organs in HIV-TB co-infection: Three of 9 patients with TB IRIS had hepatic 
involvement (in the form of rising alkaline phosphatase or hepatomegaly) in 
addition to other organ involvement as part of IRIS. Liver biopsy from one patient 
demonstrated granulomatous inflammation confirming reinstated antigen specific 
T cell immunity. 
f. Timing of HAART in relation to TB treatment does not appear to influence the 
incidence of IRIS. In this study, 17% and 27% of patients initiated on HAART 
within two months, and more than six months after initiation of ATT respectively 
developed IRIS. This data supports the decision analysis study advocating the 
early initiation of HAART in relation to TB treatment(52). 
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g. Outcome of treatment appears to be uniformly good. Most patients improved with 
treatment for tuberculosis. Both patients with CNS TB were also treated with 
steroids. 
The clinical profile of CMV, cryptococcal, herpes zoster and PML IRIS in this study was 
similar to previous reports. CMV retinitis occurred in patients with CD4 counts below 50 
cells/ml, consistent with findings in other studies. Dermatomal zoster occurred in patients 
with CD4 counts greater than 100cells/ml, which is also consistent with data reported in 
other studies(22-24). 
 
Mean time to development of IRIS after intitiation of HAART was 33 days with  the 
majority of cases occurring within two months. This was consistent with previously 
reported data. Kumarasamy et al. reported median time to IRIS as 42 days. In the 
retrospective cohort by French et al(23), 65% of IRIS cases occurred within 2 months of 
initiation of HAART while median time to IRIS was 7 weeks.  In the study by Jevtovic et 
al.(22), the median time to IRIS was 4.6 months. Ratnam et al.(24) also described a 
median time to IRIS of 12 weeks. The later onset of IRIS in these studies may be due to 
the large proportion of patients with dermatomal IRIS in these cohorts, almost all of 
which occurred after two months. This may indicate that reconstitution of antigen 
specific immunity may occur at different points of time to different antigens. The shorter 
time to development of IRIS in our study may have been a result the prospective design, 
high index of suspicion and low rates of dermatological IRIS. 
 
The mortality attributable to IRIS was low in our study. Only one patient with IRIS 
expired and this was probably due to drug toxicity. There was no mortality directly 
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attributable to IRIS. All patients improved on treatment for the underlying opportunistic 
infection and only two patients with CNS tuberculosis required treatment with steroids. 
Seven of 14 patients required hospital admission and the rest were treated as outpatients. 
This is consistent with data from other studies(22, 23). French et al reported death in only 
one out of 33 patients with IRIS(23). Manabe et al. reported a mortality of 10% in their 
case control study. However, this was a group of patients with higher disease morbidity 
as 92%  of patients were inpatients, as hospital admission was one of the selection criteria 
in this study(38). Our results indicate that most patients with IRIS improve with treatment 
of the associated OI and the syndrome is not associated with high morbidity and 
mortality.   
 
In this study, age, gender, baseline CD4 counts, absolute lymphocyte counts or mean 
body mass index (BMI) were not found to predict development of IRIS. This finding is 
different from other studies which have shown low baseline CD4 counts to predict 
development of IRIS(22, 23). These studies were retrospective, had larger sample size 
and greater proportion of patients with advanced immunodeficiency. The lack of 
association of low CD4 count with IRIS in this study may have been due to low IRIS 
event rates, smaller sample size and a smaller proportion of patients with very low CD4 
counts. Timing of initiation of HAART was also not found to be predictive of IRIS in the 
entire cohort and as well as in patients with tuberculosis. This contrasts with the findings 
of Shelburne et al. who showed that in patients with mycobacterial opportunistic 
infections and cryptococcosis, early initiation of HAART was associated with greater risk 
of IRIS (26). The lack of association of timing of ART in this study may have been due 
to the smaller proportion who had a prior OI. Patients who had prior OIs had greater rates 
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of IRIS in our study although this was not statistically significant (p=0.09). Previous TB 
and disseminated TB were also not found to be significant risk factors.  The lack of 
identifiable risk factors in this study may due to the heterogenous nature of the syndrome 
and the complex interplay between antigen burden, host immunity and genetic factors 
that has been referred to earlier. However, it is possible that larger studies may 
demonstrate significant predictive risk factors for IRIS. 
 
In this study nearly all patients were treated with nevirapine and efavirenz based 
regimens as recommended by the National AIDS Control Organisation (NACO) 
guidelines and no patients were treated with PI based regimens. Among these regimens, 
the combination of drugs did not seem to influence the occurrence of IRIS. However four 
of five patients who were initiated on emtricitabine, tenofovir and efavirenz developed 
IRIS. The significance of this observation is unclear in view of small numbers. 
Observations from literature suggest that patients on boosted protease inhibitors(BPIs) 
are at greater risk for IRIS(38). The mechanisms by which BPIs are associated with IRIS 
may be related to a greater magnitude of rise in CD4 count as compared to other 
regimens (84) and immunomodulatory effects of PIs (85, 86), (87), (88). It is possible 
that the magnitude and rate of immune reconstitution may vary with different types of 
treatment and this may influence the development of IRIS.  
The utility of the diagnostic criteria for IRIS in the Indian setting is evident in that all 14 
cases fulfilled the diagnostic criteria. Only three cases of suspected IRIS did not fulfill 
diagnostic criteria. 
. 
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In summary, the incidence of IRIS in the cohort studied was 12.8%. The spectrum of 
IRIS in our study cohort was different from western studies, which indicates that the 
spectrum of IRIS in a region may be determined by the background rates of OIs specific 
to that population. TB IRIS was the most common type of IRIS. Presentation of TB IRIS 
was varied in clinical profile, timing and severity. Multi-organ involvement in TB IRIS 
was common. A high suspicion for tuberculosis may be required in patients being 
initiated on HAART as subclinical infection is common and may present as an IRIS if 
left untreated. Most patients presented within the first two months of treatment with 
HAART. IRIS in this study was associated with fairly good outcome with treatment of 
underlying OI. Baseline CD4 counts, age, BMI and WHO stage and timing of HAART in 
relationship to OIs did not predict development of IRIS. The majority of patients 
receiving emtricitabine, tenofovir and efavirenz developed IRIS but this needs to be 
interpreted with caution in view of small number of cases. The small sample size and loss 
to follow up are important limitations of this study. Further prospective studies are 
required to study the complexity of factors that determine the occurrence of IRIS in India 
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Conclusions 
 
The important conclusions of this study are as follows:  
 
1. 14 cases of IRIS were diagnosed in a cohort of 109 patients initiated on HAART 
with an incidence of 12.8% (CI- 7.2-20.6%).  
 
2. TB was the most commonly identified  IRIS in this study contributing to two 
thirds of all the IRIS (9/14 patients). This reflects the high burden of TB disease 
in our patients. 81.6% of all prior opportunistic infections in this cohort (40/49) 
were due to TB.  There were no cases of MAC IRIS, Hepatitis B and C IRIS, 
reflecting the absence of these infections in this cohort of patients. The absence of 
Pneumocystis IRIS may reflect the low frequency of prior PCP infection (2 cases) 
in this cohort probably due to widespread use of TMP/SMX prophylaxis. 
Dermatological IRIS was also uncommon.  
 
3. The majority of patients who developed IRIS had not previously been diagnosed 
to have the same opportunistic infection causing the IRIS (9/14 patients). It 
appears that sub-clinical opportunistic infections, particularly due to TB are 
common and difficult to clinically detect prior to initiation of HAART.   
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4. The clinical profile of TB, Cryptococcal, CMV, Herpes zoster and PMLE IRIS in 
this study was similar to previous reports.  Of the nine patients with TB IRIS five 
presented with localised forms of TB, pulmonary, lymph node, meningitis and 
skin involvement and four presented with multi-organ system involvement. 
 
5. Time to development of IRIS following initiation of HAART varied from 4-120 
days with a mean of 33 days. 85% of patients developed IRIS within two months 
of initiation of HAART.  
 
6. Twelve of 14 patients were managed with anti-infective treatment alone and 2 
cases of TB meningitis were treated with steroids. The clinical outcomes of 
patients were uniformly good except for one patient with cryptococcal meningitis 
who died due to drug toxicity. There was no IRIS related mortality. 
 
7. Clinical stage, BMI, baseline CD4 count, prior opportunistic infection, type of 
ART, timing of HAART treatment were not found to be significant risk factors in 
the development of IRIS.   
 
8. The majority of patients on Efavirenz, emtricitabine and tenofovir developed IRIS 
(4/5 cases). This observation should be interpreted cautiously in view of the small 
numbers and requires further study.  
 
In summary, IRIS is a clinically important syndrome in HIV patients initiated on 
HAART in the Indian setting. When compared to other studies, IRIS appears to be a 
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heterogeneous syndrome that varies with respect to event rates, opportunistic 
spectrum and clinical severity depending on the setting. This variability probably 
reflects the complex interaction between antigen burden, host immune response and 
genetic predisposing factors that underlie the pathophysiology of IRIS. In India, it is 
almost exclusively a result of exuberant immune response to widespread TB infection 
in patients with HIV infection. The lack of identifiable risk factors in this study may 
be due to heterogeneous nature of the syndrome and the complex interplay of factors 
that play a role in the underlying pathophysiology. Further studies are required to 
better delineate the pathophysiology of this syndrome and its predictors in the Indian 
setting. 
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Objectives of the study: 
 
To study the incidence and predictive factors of immune reconstitution inflammatory 
syndrome (IRIS) among a cohort of patients initiated on HAART and describe this 
syndrome among them. 
 
Methods: 
 
A cohort of patients with HIV infection initiated on HAART at Christian Medical 
College and Hospital and government ART centres was prospectively followed up for a 
minimum of six months to observe for the development of IRIS. Baseline CD4 cell 
counts, WHO staging of patients, BMI and presence of previous opportunistic infections 
were recorded in all patients. Overall incidence and opportunistic infection specific 
incidences of IRIS were calculated. Clinical presentations, investigations and outcome of 
patients with IRIS were recorded. Baseline characteristics were compared between 
patients who developed IRIS and those who did not, and predictors for IRIS were 
identified.  
 
 
 
Results: 
 
 
14 cases of IRIS were diagnosed in a cohort of 109 patients initiated on HAART with an 
incidence of 12.8% (CI- 7.2-20.6%). The incidence of individual IRIS syndromes were: 
 3
TB IRIS 8% (CI 3.8%, 15.1%), CMV IRIS 1.8% (CI 0.2%, 6.5%), Cryptococcal IRIS 1% 
(CI 0.02%,6.4%), PMLE IRIS 1% (CI 0.02%,6.4%) and Herpes zoster IRIS  1% (CI 
0.02%,6.4%). The time to development of IRIS following initiation of HAART varied 
from 4-120 days with a mean of 33 days. 85% of patients developed IRIS within two 
months of initiation of HAART. In this study IRIS was associated with good outcomes. 
Clinical stage, BMI, baseline CD4 count, prior opportunistic infection, type of ART, 
timing of HAART treatment were not found to be significant risk factors in the 
development of IRIS. 
 
Conclusions: 
 
IRIS is an important clinical problem in this region which occurred at an incidence of 
12.8% in this study. TB was the most common opportunistic infection presenting as IRIS 
which may be a reflection of the high prevalence of manifest or subclinical tuberculosis 
co-infection in patients with HIV being initiated on HAART in our setting. No significant 
predictors for IRIS were identified in this study. Outcomes in patients with IRIS appear 
to be fair with treatment of underlying opportunistic infections.  
 
 
Appendix 
IRIS patients: presentations 
A detailed discussion of manifestations of various cases of IRIS along with diagnostic 
criteria, treatment and follow up is outlined below: 
 
TB IRIS(Cases A - I) 
Case A: 
 
History and examination: 
A 33 year old man with stage IV disease (wasting and AIDS dementia) with a baseline 
CD4 count of 8 cells/ml was initiated on a combination of Stavudine, lamivudine and 
Nevirapine. Two months later, he developed high grade fever and dry cough. On 
examination, he was icteric and had posterior cervical lymphadenopathy and 
hepatosplenomegaly. He had no history of tuberculosis in the past.  
 
Investigations: 
Ultrasound abdomen: Liver size increased to 17.6 cm from 14.9 cm on previous 
ultrasound. Splenomegaly of 13cm. New 6mm mesenteric lymph nodes not seen on 
previous ultrasound abdomen.   
Liver function tests: 
  
 Liver function tests Baseline At time of worsening 
Total bilirubin 0.5mg% 3.7mg% 
Direct bilirubin 0.2mg% 3.1% 
Total protein 8.4g% 5.9g% 
Serum albumin 3.2g% 2.3g% 
SGOT 60IU/ml 150IU/ml 
SGPT 31IU/ml 90IU/ml 
Alkaline phosphatise 139 IU/ml 634IU/ml 
 
Chest X ray showed diffuse alveolar infiltrates.  
Induced sputum was positive for acid fast bacilli.  
His repeat CD4 count was 25 cells/ml. 
 
Diagnosis: 
Disseminated tuberculosis, IRIS. 
 
Discussion: 
This patient presented with paradoxical worsening following initiation of HAART. He 
had high grade fever, worsening hepatosplenomegaly, lymphadenopathy, new infiltrates 
on chest radiograph and rising alkaline phosphatase consistent with an inflammatory 
response involving multiple organs. Induced sputum showed acid fast bacilli, confirming 
the diagnosis. CD4 counts showed a rise from baseline. This patient had been noted to 
have hepatomegaly at baseline screening prior to initiation of HAART. Hepatomegaly 
worsened and splenomegaly and intra-abdominal lymph nodes appeared after initiation of 
HAART.  He had high grade fever with marked rise in alkaline phosphatase. This 
indicates that he had underlying tuberculosis which manifested following initiation of 
HAART. His course was atypical in acute onset with high grade fever, pulmonary, 
hepatic and lymph node involvement. This patient satisfied criteria for IRIS.  
 
Treatment and follow up: 
This patient was discharged on anti-tuberculous therapy and HAART. He improved on 
treatment and was well on follow up.  
 
 
Case B: 
 
History and examination: 
A 32 year old man with clinical stage I HIV infection and CD4 count of 254 cells/ml was 
initiated on Zidovudine 300mg twice daily, Nevirapine 200mg once daily and 
Lamivudine 150mg twice daily. Four months later, he presented with a swelling in the 
left submandibular region. He had no associated fever or decreased appetite. He had 
never had tuberculosis in the past.  
 
On examination, he had a 4.5 X 4.5cm swelling in the left submandibular region. The 
swelling was tender. There was no associated warmth or redness. 
 
Investigations: 
Fine needle aspiration from the submandibular lymph node showed epitheloid 
granulomas 
CD4 count was 648 cells/ml. 
 
Diagnosis: 
Tuberculous lymphadenitis, Immune reconstitution inflammatory syndrome. 
 
Discussion 
This patients presented with all features of IRIS. He developed enlarged submandibular 
lymph nodes following initiation of HAART. He had features of an inflammatory 
response on histology. The clinical presentation was atypical in the localised presentation 
of lymphadenitis as well as the unusual site of involvement. Immune reconstitution was 
evident by the rise in CD4 count as well as  presence of granulomas on fine needle 
aspiration of the lymph node suggesting a specific T cell response.  
 
Treatment and follow up: 
He was initiated on treatment for tuberculosis. The swelling gradually subsided on 
treatment. He was well on follow up.  
 
Case C: 
History and examination: 
A 76 year old man with WHO stage IV HIV infection with a baseline CD4 on 168 
cells/ml was initiated on lamivudine, nevirapine and stavudine combination therapy. One 
month later, he developed a 1 X 1 cm left supraclavicular lymph node swelling. He had 
no other systemic symptoms. 
 
Investigations: 
Lymph node biopsy: Caseating granulomatous inflammation consistent with tuberculosis. 
No acid fast bacilli were seen. 
 
Diagnosis: 
Tuberculous lymphadenitis; Immune reconstitution inflammatory syndrome. 
 
Discussion: 
This patient developed paradoxical worsening in the form of new onset lymphadenopathy 
following initiation of HAART. Immune reconstitution and inflammatory response was 
evidenced by granulomatous inflammation on lymph node biopsy. Localised presentation 
of lymphadenitis is an atypical presentation in an immunocompromised patient. He fits 
criteria for typical immune reconstitution inflammatory syndrome. 
 
Follow up and treatment outcome: 
He was initiated on Category I ATT and changed to an efavirenz based HAART regimen. 
The lymph node swelling subsided and he was well on subsequent follow up. 
 
Case D: 
History and examination: 
A 49 year old lady with stage IV HIV infection and CD4 counts of 64 cells/ml was 
diagnosed to have sputum positive pulmonary tuberculosis with tuberculous 
lymphadenitis. A fine needle aspiration from an enlarged cervical lymph nodes showed 
one lymphohistiocytic aggregate. Six months later, she was initiated on stavudine, 
lamivudine and Nevirapine. Two months following initiation of HAART, she developed 
worsening lymphadenopathy and fever. She had a 2 X 2 cm palpable lymph node in the 
left middle deep cervical group of lymph nodes. 
 
Investigations: 
CD4 count at time of worsening:188 cells/ml. 
 
Diagnosis: 
Tuberculous lymphadenitis; Immune reconstitution inflammatory syndrome. 
 
Discussion: 
This patient had paradoxical worsening of a previous opportunistic infection while on 
HAART. Enlargement of cervical lymph nodes with high grade fever was consistent with 
an inflammatory response. Localised presentation was atypical in an 
immunocompromised patient. Immune reconstitution was demonstrated by a rising CD4 
count. She satisfied criteria for immune reconstitution inflammatory syndrome. 
 
Follow up and outcome: 
She was referred for a repeat fine needle aspiration of the lymph node. She has not 
followed up subsequently. 
 
 
 
Case E: 
History and examination:  
A 28 year old lady was diagnosed to have TB meningitis with stage IV HIV infection 
when she was admitted to the hospital with fever, headache, vomiting and altered 
sensorium. Her CSF showed 110 cells with 65% lymphocytes, sugar of 29mg% with 
concomitant plasma glucose of 140 mg% and protein of 129 mg%. She was also noted to 
have cervical lymphadenopathy. Lymph node biopsy showed caseous necrosis bordered 
by confluent granulomas, epitheloid histiocytes and langhan’s giant cells. Acid fast 
bacilli were present. She was initiated on category I ATT along with tapering steroids on 
which her symptoms improved. She was initiated on Stavudine, lamivudine and 
Nevirapine one month later. Her baseline CD4 count was 240 cells/ml. One month later, 
she presented to the emergency department with headache and vomiting. On 
examination, she had neck stiffness. She was not in altered sensorium and had no history 
of fever or seizures. 
 
Investigations: 
CSF analysis: Cells: WBC 490/ul with 70% lymphcytes, protein 240 mg%, glucose 37 
mg%. Cryptococcal smears and cultures were negative. Mycobacterial smears and 
cultures were negative. 
Repeat CD4 counts: 617/ul.  
 
Diagnosis: 
Tuberculous meningitis; Immune reconstitution inflammatory syndrome. 
 
Discussion: 
This patient had paradoxical worsening of symptoms following initiation of HAART. She 
had been on treatment for tuberculous meningitis with documented improvement in 
symptoms prior to initiation of HAART. She had an atypical course of TB meningitis 
with paradoxical worsening following initial improvement in symptoms on treatment. 
Her CSF analysis showed an markedly cellular response. Immune reconstitution was 
evidenced by rising CD4 counts. This patient satisfied all criteria for IRIS.  
 
Follow up and outcome: 
She was continued on ATT and HAART and her symptoms improved without any further 
treatment.  
 Case F: 
 
History and examination: 
A 39 year old male with Stage IV HIV infection was diagnosed to have tuberculous 
meningitis when he presented to his local hospital with prolonged fever, headache and 
weight loss. His CSF showed elevated protein of 102mg% with low glucose of 48mg% 
and 7 cells all of which were lymphocytes. MRI showed multiple ring enhancing lesions 
suggestive of tuberculomas. He was initiated on ATT and tapering doses of steroids. His 
fever had subsided and other symptoms  markedly improved. He was diagnosed to have 
HIV infection at this point of time and was referred to our centre for further treatment. 
His CD4 count at presentation was 40 cells/ml. Clinical examination was normal. Fundus 
was normal. He had no focal neurological deficits. There were no meningeal signs. He 
was initiated on HAART (Efavirenz 600mg once daily, Tenofovir 300mg once daily, 
Emtricitabline 200mg once daily) 24 days after initiating treatment for TB meningitis.  
Nine days later he developed fever associated with headache and vomiting. He developed 
altered sensorium and had one episode of generalised tonic clonic seizures.  
 
On examination, his sensorium was altered. Fundus showed blurred margins. Neck 
stiffness was present. There were no focal deficits. He had hepatosplenomegaly.  
 
Investigations: 
CSF counts: 50 WBC/ul, 96% lymphocytes and 4% polymorphs 
CSF protein: 89 mg% 
Glucose: 47 mg% 
CSF cultures: smears negative for acid fast bacilli. India ink examination negative. 
Mycobacterial and fungal cultures did not show any growth. 
Alkaline phosphatase: 592 IU/ml (baseline Alkaline phosphatase:160IU/ml) 
Liver biopsy: Non-caseating granulomatous inflammation 
Repeat CD4 count was 1020 cells/ml.  
 
Diagnosis: 
Tuberculous meningitis, Immune reconstitution inflammatory syndrome 
 
Treatment:  
He was continued on TB treatment, steroids as well as HAART. He developed efavirenz 
induced visual hallucinations. Therefore, his ART regimen was changed from an 
efavirenz to boosted protease inhibitor based regimen. On this he stopped having 
hallucinations. His fever and altered sensorium improved on treatment. He was well on 
follow up. 
 
Discussion: 
This patient had a typical IRIS. He developed paradoxical worsening soon after initiation 
of HAART. CSF showed an inflammatory response. Alkaline phosphatase levels 
increased. Liver biopsy confirmed granulomatous inflammation, indicative of a good 
cellular immune response. He had an atypical clinical presentation of TB meningitis with 
paradoxical worsening following initial improvement with ATT and steroids. Hepatic 
involvement with marked elevation in alkaline phosphatase was also atypical. CD4 
counts showed a marked rise, indicating immune reconstitution. This patient also 
developed drug toxicity further confusing his clinical picture. Drug toxicity may be 
difficult to distinguish from paradoxical worsening.  
  
 
Case G: 
History and examination: 
A 38 year old lady with WHO stage III HIV infection diagnosed as sputum negative 
pulmonary tuberculosis on anti-TB treatment was initiated on HAART (Stavudine, 
lamivudine and efavirenz combination therapy) one month later. Two weeks following 
initiation of anti-retroviral therapy, she presented to the outpatient with fever, pruritis, 
jaundice and hepatosplenomegaly with a diffuse erythematous rash over the body. She 
was thought to have a drug rash. TB treatment was discontinued at the government 
hospital. Since the indication for initiation had been empirical, it was not continued. Her 
baseline CD4 had been 154 cells/ml. One month later, she presented with a tender 
subcutaneous swelling in the right thigh which subsequently ulcerated forming an ulcer 4 
cm in diameter with undermined edges.  
 
Investigations: 
Ulcer edge biopsy: granulomatous inflammation consistent with tuberculosis. Repeat 
CD4 count: 418/ul.  
  
Diagnosis: 
Tuberculous ulcer, right thigh; Immune reconstitution inflammatory syndrome. 
 
 
Discussion: 
This patient had been diagnosed to have sputum negative pulmonary tuberculosis on the 
basis of a chest X ray showing bilateral miliary shadows. Following initiation of 
HAART, she developed skin rash, hepatitis and hepatosplenomegaly. Drug rash was 
considered and TB treatment was discontinued. After two months of initiation of 
HAART, she developed an ulcer on her right thigh, the biopsy from which showed 
granulomatous inflammation consistent with tuberculosis. This patient probably had 
inadequately treated disseminated tuberculosis and developed an immune reconstitution 
inflammatory syndrome following return of immunity towards persisting antigens. She 
satisfied all criteria for IRIS. Inflammation is clearly evidenced by granulomatous 
inflammation on biopsy and immune reconstitution by the marked rise in CD4 count 
from baseline. This is an atypical presentation with pulmonary involvement followed by 
localised skin involvement in the form of ulceration.  
 
Follow up and outcome: 
She was initiated on Category I ATT by RNTCP and Efavirenz based HAART regimen. 
Her ulcer healed over a period of three months. She was well on follow up.    
  
Case H: 
History and examination: 
A 55 year old diabetic and hypertensive with HIV infection– WHO stage I disease and 
CD4 count of 161 cells/ml at initiation of HAART (emtricitabine, tenofovir and 
efavirenz) presented with history of fever five days after initiation of ART. The fever was 
high grade associated with cough with purulent expectoration. He had associated left-
sided chest pain. There was no associated breathing difficulty. On examination, he was 
febrile. He was not in respiratory distress. Examination of the respiratory system was 
normal. 
 
Investigations: 
Total WBC count:  10,900/cu mm 
Differential count: 85% neutrophils, 1% eosinophils, 8% lymphocytes and 6% 
monocytes.  
Alkaline phosphatase: 151 IU/ml (baseline alkaline phosphatase: 92 IU/ml) 
 
Chest X ray showed new infiltrates in the left lower zone. 
Sputum for AFB: Two smears showed a few acid fast bacilli 
Repeat CD4 count: 162 cells/ml  
Diagnosis:  
Sputum positive pulmonary tuberculosis, Immune reconstitution inflammatory syndrome. 
 Treatment: 
He was initiated on anti-TB treatment, which he took regularly. His symptoms improved 
and infiltrates completely resolved. He was well at follow up six months later. 
 
Discussion: 
This patient fits the criteria for IRIS. He had paradoxical worsening following initiation 
of HAART. He presented with acute onset cough, pleuritic chest pain, high grade fever, 
worsening chest infiltrates and sputum positivity for acid fast bacilli within one week 
following initiation of HAART. This is an atypical presentation of pulmonary 
tuberculosis. High grade fever with acute onset of symptoms were suggestive of an 
inflammatory response. Although, CD4 count did not show a significant rise, it is well 
known that viral load suppression occurs several weeks prior to rise in CD4 counts.  
 
 
Case I: 
A 38 year old man with stage IV HIV infection was initiated on Tab. Zidovudine 300mg 
twice daily, Tab. Lamivudine 150mg twice daily and Tab. Nevirapine 200mg twice daily. 
He had been diagnosed to have disseminated TB (US guided FNAC from peripancreatic 
lymph nodes showing granulomatous inflammation consistent with TB) eight months 
prior to initiation of HAART. He had been treated with regular ATT for six months. 
Baseline CD4 counts were 154 cells/ml. Fifteen days after initiating HAART, he 
developed high grade fever with cough.  Respiratory system examination was normal. 
Abdominal examination revealed that he had hepatosplenomegaly. 
 
Investigations: 
Sputum smears showed a few acid fast bacilli.  Subsequent cultures grew Mycobacterium 
tuberculosis.  
Chest X ray showed a left lower zone consolidation.  
Repeat CD4 counts were 175 cells/ml.  
 
Diagnosis and criteria: 
Sputum positive pulmonary tuberculosis, immune reconstitution inflammatory syndrome. 
 
Discussion: 
This patient presented with a typical IRIS. He had paradoxical worsening after initiation 
of HAART. He had completed TB treatment and had been cured. Two weeks after 
starting HAART, he developed high grade fever and breathlessness associated with chest 
infiltrates and sputum acid fast bacilli positivity. High grade fever with breathlessness 
was consistent with an inflammatory response. He had an atypical course with an acute 
onset, lower zone consolidation and enlargement of liver and spleen. CD4 counts showed 
a modest increase consistent with immune reconstitution.  
 
Treatment and follow up: 
He was initiated on Category II ATT by RNTCP on which his symptoms improved. 
However, he was found to be persistently sputum positive after three months of regular 
Category II ATT. He was then treated for multi-drug resistant tuberculosis. 
 
CMV IRIS (Cases J and K) 
Case J: 
 
History and examination: 
A 29 year old man with stage IV disease was initiated on Tab. Stavudine 30mg twice 
daily, Lamivudine 150mg twice daily and Nevirapine 200mg once daily. His baseline 
CD4 was 7 cells/ml. He also had hepatitis B coinfection. He had been admitted with 
salmonella typhimurium septicaemia and Pneumocystis jirovecii pneumonia two weeks 
prior to initiation of HAART. He had also been diagnosed to have latent syphilis. Eleven 
days after initiation of HAART, he developed fever, cough and decreased vision in his 
right eye. Fundoscopy showed an appearance suggestive of CMV retinitis. 
 
Investigations: 
Repeat CD4 count 161 cells/ml 
 
Diagnosis: 
CMV retinitis, Immune reconstitution inflammatory syndrome 
 
Discussion: 
This patient had clinical deterioration following initiation of HAART. His presentation 
was not atypical. CMV uveitis and vitritis are atypical manifestations of CMV that often 
occur during immune reconstitution. However, CMV retinitis is also known to occur as 
an IRIS. He had an inflammatory response in the form of high grade fever associated 
with acute onset decrease in vision. CD4 counts showed a rise confirming immune 
reconstitution. 
 
Follow up: 
He was initiated on IV gancyclovir. His vision improved only marginally.  
 
 
Case K: 
History and examination: 
A 43 year old female was diagnosed to have carcinoma breast for which she underwent 
simple mastectomy with axillary node sampling in January 2007. She had been on 
chemotherapy and had received four cycles of chemotherapy and external radiotherapy. 
She was diagnosed to have HIV infection (stage 4) at time of diagnosis of carcinoma 
breast. Her baseline CD4 counts were 42 cells/ml. She was diagnosed to have 
disseminated TB on 16/6/2007 when she presented with fever and hepatomegaly. Her CT 
thorax showed mediastinal lymphadenopathy with central hypodensities and she was 
empirically initiated on TB treatment. She became afebrile. She presented with dysphagia 
to the outpatient three weeks later. She was initiated on treatment with fluconazole for 
probable oesophageal candidiasis. However, even after completion of two weeks of 
treatment, her symptoms continued to persist. An upper GI scopy at this point revealed 
circumferentially ulcerated mucosa with extensive sloughing. Biopsy taken showed an 
inflammatory exudate with necrotic material and candidal infestation. She was treated 
with amphotericin considering resistant oesophageal candidiasis. She was initiated on a 
combination of  tenofovir, emtricitabine and efavirenz one month after onset of 
dysphagia (17/8/07). Two weeks following this she developed choking sensation and 
regurgitation while taking food. Fundus examination revealed peripheral CMV retinitis. 
 
Investigations: 
Endoscopy showed oesophageal ulceration with a tracheo-oesophageal fistula. 
Biopsy was negative for inclusion bodies. 
Serum CMV PCR positive 
Serum CMV IgM antibody positive 
Repeat CD4 counts: 131 cells/ml 
 
Diagnosis: 
CMV retinitis and probable CMV oesophagitis with tracheo-esophageal fistula; immune 
reconstitution inflammatory syndrome. 
 
Discussion: 
This patient presented with a typical IRIS. She had paradoxical worsening after initiation 
of HAART. Serial endoscopies demonstrated worsening ulceration of oesophagus with 
development of a tracheo-oesophageal fistula which had not been present prior to 
initiation of HAART. Fundus examination revealed CMV retinitis, indicating a possible 
common etiology. This is an atypical presentation of CMV oesophagitis as a tracheo-
oesophageal fistula. Oesophageal ulceration and development of a tracheo-oesophageal 
fistula is suggestive of marked inflammation. Immune reconstitution was evidenced by a 
rising CD4 count.  
 
Treatment and outcome: 
She was placed on an NG tube following which a feeding jejunostomy was done. As she 
had leucopenia, gancyclovir was not initiated. However, after 6 weeks of ART, her 
counts improved and CMV retinitis resolved spontaneously. She was discharged to 
continue jejunostomy feeds. She was discharged on anti-tuberculous therapy and 
HAART.  
 
Herpes Zoster IRIS 
Case L: 
History and examination: 
A 38yr old man with stage I HIV infection and CD4 count of 177 cells/ml was initiated 
on Tab. Efavirenz 600mg once daily Tenofovir 300mg once daily and Emtricitabline 
200mg once daily.  Twenty seven days later he developed vesicular lesions associated 
with pain over his chest in the T7 and T8 dermatomes.  
 
Investigations: 
CD4 at time of deterioration: 626 cells/ml 
 
Diagnosis: 
Dermatomal herpes zoster, Immune reconstitution inflammatory syndrome. 
 
Discussion: 
This patient had a typical IRIS. He developed localised dermatomal herpes zoster 
following initiation of HAART associated with severe pain. He had features of an 
inflammatory response in the form of severe associated pain. Localised herpes zoster is 
an atypical presentation of zoster in an immunocompromised patient. Repeat CD4 counts 
demonstrated marked immune reconstitution.  
 
Follow up and treatment: 
He was initiated on Acyclovir. Lesions healed within 15 days. He was well on follow up.  
 
Cryptococcal IRIS 
Case M 
History and examination: 
A 38 year old man with a baseline CD4 count of 119 cells/ml and stage I HIV infection 
was initiated on ART (Zidovudine 300mg twice daily, Lamivudine 150mg twice daily 
and Nevirapine 200mg twice daily). He presented to the emergency department three 
months later with severe headache, vomiting, high grade fever and altered sensorium. He 
had meningeal signs. He had bilateral papilloedema on fundoscopy.  
 
Investigations: 
CSF counts: Total WBC count 170/ul, 90% lymphocytes, 10% polymorphs; glucose 34 
mg%; protein 84 mg%.  
CSF smear:  yeast like organisms.  
CSF culture: Cryptococcus neoformans. 
CT brain: Mild hydrocephalus.  
 
LFT: 
Total bilirubin: 1.6mg% 
Direct bilirubin: 0.7mg% 
Total protein: 6.5g% 
Serum albumin: 2.8g% 
SGOT: 197 IU/ml 
SGPT: 234 IU/ml 
Alkaline phospatase: 201 IU/ml 
 
Diagnosis: 
Cryptococcal meningitis; Immune reconstitution inflammatory syndrome. 
 
 
Discussion: 
This patient presented with paradoxical worsening three months following initiation of 
anti retroviral therapy. He was diagnosed to have cryptocococcal meningitis. Elevated 
CSF counts were suggestive of an inflammatory response. Repeat CD4 counts were not 
available to confirm immune reconstitution. Acute deterioration in symptoms and 
presence of meningeal signs with a cellular response was an atypical presentation of 
cryptococcal meningitis. This clinical picture is consistent with an immune reconstitution 
inflammatory syndrome. 
 
Follow up and outcome: 
He was initiated on amphotericin B which was discontinued due to renal failure and 
persistent hypokalemia. He had a sudden cardiac arrest which was probably secondary to 
amphotericin induced hypokalemia.  
 
PMLE IRIS: 
Case N: 
History and examination: 
A 45 year old man with clinical stage IV HIV infection had presented to the outpatient 
with imbalance on walking for 2 months. This was insidious in onset. He had history of 
falling towards the left. This was associated with slurring of speech. He had history of 
chronic alcohol consumption for ten years which he had stopped at onset of symptoms. 
He also had history of TB lymphadenitis in 2005 for which he had received TB treatment 
for eight months regularly. A diagnosis of probable alcohol related cerebellar dysfunction 
was made. His CD4 count was 116 cells/ml. He was initiated on Nevirapine 200mg bd, 
Zidovudine 300mg bd and Lamivudine 150mg bd. He presented to the emergency 
department with worsening symptoms 3 days later. He had significant worsening of his 
ataxia. He was unable to stand or walk. He had increased slurring of speech. He was 
admitted and evaluated. On examination, he had bilateral nystagmus, past pointing (more 
on the left side) and dysdiachokinesia. He also had decreased sensation over the left side 
of the face.  
 
Investigations: 
CD4 levels: 151 cells/ml 
Serum B12 levels 224 pg/ml 
Folate levels >24ng/ml 
Cerebrospinal fluid: total WBC 2/cu mm, all lymphocytes, RBC 90(30% crenation), 
protein 47mg% and glucose level 58mg% 
Cerebrospinal fluid cultures negative for bacterial, mycobacterial and fungal growth.  
Cerebrospinal VDRL negative 
MRI brain: Long TR hyperintensity in left cerebellar matter extending into ipsilateral 
middle and superior cerebellar peduncles and dorsal part of left side of pons. A smaller 
hyperintensity visualised in the right superior cerebellar white matter and cerebellar 
peduncles. Multiple patchy long TR hyperintensities in left centrum semi-ovale and 
posterior periventricular region.  No appreciable enhancement seen on the post contrast 
study. Features in favour of cerebellar demyelination. 
Ultrasound abdomen: Normal. No evidence of chronic liver disease 
 
Diagnosis: 
Progressive multifocal leukoencephalopathy, Immune reconstitution inflammatory 
syndrome. 
 
Discussion: 
This patient had paradoxical worsening following initiation of HAART in the form of 
acute worsening of cerebellar symptoms and signs with dysarthria. MRI showed 
cerebellar demyelination extending into the left pons consistent with a diagnosis of PML. 
This presentation was atypical as he developed sudden worsening of symptoms that had 
been progressing insidiously over a period of two months. Immune reconstitution was 
evidenced by a rising CD4 count. Therefore,this patient satisfied all criteria for IRIS.  
 
Follow up: 
HAART was continued. His condition gradually improved. He was well at six months 
follow up with significant improvement in deficits. 
 
 
 
 
Patients with paradoxical worsening but did not fulfill the 
criteria for IRIS 
 
Case O: 
History and examination: 
A 41 year old lady with stage IV disease and CD4 count of 88 cells/ml was initiated on 
Zidovudine 300mg twice daily, Lamivudine 150mg twice daily and Efavirenz 600mg 
once daily.  This was changed to a stavudine based regimen two months later when she 
developed anemia. She had history of chronic large bowel diarrhoea since 2005 with 
weight loss. Stool examination for parasites had been negative. She had been diagnosed 
to have pulmonary TB three months ago (perihilar lymphadenopathy on CT thorax) and 
had been initiated on ATT which she was taking regularly.  Three months after initiating 
HAART, she presented with severe headache, vomiting, fever for three days with altered 
sensorium for one day. She had one episode of generalised tonic clonic seizures in the 
emergency department. On examination, she had neck stiffness. She was unresponsive. 
Her pupils were dilated and fixed. Dolls eye was absent. Fundoscopy showed 
papilloedema.  
 
 
Investigations: 
CT brain: marked cerebral edema with basal meningeal enhancement and focal 
hypodensities in both occipital regions suggestive of cerebritis.  
Chest X ray: Left sided ill defined infiltrates. 
Total WBC count: 17500/ul with 1% myelocytes, 1% metamyelocytes, 4% band forms, 
82% neutrophils, 9% lymphocytes and 3% monocytes.  
Liver function tests: 
Total bilirubin: 0.4mg% 
Direct bilirubin: 0.2mg% 
Total protein: 7.6g% 
Serum albumin: 2.9g% 
SGOT: 16 IU/ml 
SGPT: 83 IU/ml 
Alkaline phospatase: 180 IU/ml 
 
Electrolytes: 
Serum sodium: 123meq/dl 
Potassium: 3.4meq/dl 
Bicarbonate: 3meq/dl 
Creatinine 4.1mg% 
 
Haemoglobin: 8mg% 
Prothrombin time: 16.9 seconds 
Activated thromboplastin time: 43 seconds 
 
Arterial blood gas: 
pH: 6.77 
 
Blood cultures: negative for growth 
Repeat CD4 count: 116 cells/ml 
 
Discussion: 
This patient presented paradoxical worsening following initiation of HAART. She had 
features suggestive of meningo-encephalitis. Lumbar puncture was not done due to 
features of high intracranial pressure. She had a high peripheral blood count with a left 
shift. She had multiorgan dysfunction with severe metabolic acidosis. Chest X ray 
showed an ill-defined left sided infiltrate. Differential diagnosis included pneumococcal 
meningitis, tuberculous meningitis and fungal meningitis. However, the acute 
presentation, high counts and multi-organ dysfunction were more in favour of a pyogenic 
meningitis. She was initiated on crystalline penicillin, anti-tuberculous and anti-fungal 
therapy.  However, her condition did not improve. Prognosis was discussed with relatives 
and supports were withdrawn. She expired within three days. Although this patient 
presented with paradoxical worsening following initiation of HAART, the diagnosis of 
IRIS could not be confirmed. 
 
 
Case P 
History and examination: 
A 40 year old man was diagnosed to have tuberculous lymphadenitis and stage III HIV 
infection with CD4 counts of 124/ul. He was initiated on a combination of lamivudine, 
Stavudine and Efavirenz two weeks later. Ten days following initiation of HAART he 
presented with history of high grade fever for one week associated with chills and rigors. 
On examination, his liver was palpable 2cm below the right costal margin. There was no 
splenomegaly or lymphadenopathy.  
 
Investigations:  
Total WBC count: 5400/ul, 79% neutrophils, 1% eosinophils, 9% monocytes and 11% 
lymphocytes. 
Liver function tests: 
Total bilirubin: 0.5mg% 
Direct bilirubin: 0.2mg% 
Total protein: 8.5g% 
Serum albumin: 3.2g% 
SGOT: 45 IU/ml 
SGPT: 45 IU/ml 
Alkaline phospatase: 88 IU/ml 
 
Blood cultures: No growth 
Malarial smears: negative 
Scrub typhus IgM ELISA: negative 
Leptospira IgM ELISA: negative 
Typhidot: negative 
Dengue IgM: negative 
 
Repeat CD4:169 cells/ml 
 
Discussion: 
This patient had paradoxical worsening following initiation of HAART. He had been 
diagnosed to have tuberculous lymphadenitis for which he was on treatment. He 
presented with fever and hepatomegaly. Evaluation for the fever was negative. His fever 
subsided without any specific treatment. This patient does not satisfy criteria for IRIS. 
Although he had an episode of paradoxical worsening following initiation of HAART, 
this was not clearly attributable to his underlying opportunistic infection. High grade 
fever was suggestive of an inflammatory response. Immune reconstitution was 
demonstrated by a rise in CD4 count. However, all criteria for IRIS were not satisfied. 
 
Follow up and outcome: 
This patient was well on six months follow up.  
  
Case Q: 
History and examination: 
A 40 year old man with WHO stage III HIV infection with baseline CD4 counts of 61 
cells/ml was diagnosed to have sputum positive pulmonary tuberculosis for which he was 
treated with category I anti-tuberculous therapy (DOTS). Following completion of six 
months of treatment, he was initiated on Zidovudine, Lamivudine and Nevirapine. 
Following initiation of HAART, he developed itchy papular lesions over the back. A 
diagnosis of probable scabies was made. He was treated with ivermectin with which 
lesions resolved.  
 
Discussion: 
This patient had paradoxical worsening following initiation of HAART. However, 
immune reconstitution was not demonstrated. This patient does not satisfy criteria for 
IRIS. Scabies has not been documented as an IRIS in the literature. 
 
Follow up and outcome: 
The patient was well at follow up. 
 
S..no Name sex age hosp no. CD4 WHO stageALC ht wt BMI date of HAARtplace of HAARTPrev OI?
1 Appa Rao M 51 875687C 100 3 2340 167 76 27.25089 11/4/2006 CMC Y
2 MEEna F 30 146379C 190 1 840 150 50 22.22222 11/4/2006 CMC N
3 Gandhi F 33 919802C 49 4 1036 143 40 19.56086 12/2/2006 CMC Y
4 Bhasker M 37 746868C 45 4 177 158 45 18.02596 11/1/2006 CMC Y
5 Murugan M 33 453561C 198 3 3102 161 61 23.53304 2/21/2007 ED N
6 Sri Ram M 52 915830C 113 3 1575 175 45 14.69388 11/15/2006 CMC N
7 Sudhir KumarM 40 888760C 162 4 2436 167 47 16.85252 11/15/2006 CMC N
8 Uma ShankarM 40 919689c 34 4 360 164 42 15.6157 11/9/2006 CMC N
9 AnanthalakhmiF 40 909260C 77 4 264 156 35 14.38199 11/17/2006 CMC Y
10 Kumar S M 37 308781c 91 4 689 168 41 14.52664 12/3/2006 ED Y
11 Ramesh M 43 949854c 185 1 1650 172 64 21.63332 1/3/2007 ED N
12 Pitchandi M 37 953095c 48 3 600 175 75 24.4898 1/24/2007 CMC Y
13 Dr. Jued AntonM 33 960639C 27 4 720 158 60 24.03461 1/23/2007 CMC Y
14 Kamalam F 33 898496c 111 1 693 156 39 16.02564 2/14/2007 CMC N
15 VijaykumariF 39 401630C 240 1 1836 170 48 16.609 1/8/2007 CMC N
16 Raju DRC M 39 925526C 68 4 600 168 64 22.67574 12/21/2006 CMC Y
17 Jamuna F 41 609862C 88 4 1504 150 41 18.22222 6/12/2007 ED Y
18 Velangini F 40 648049C 215 1 1829 163 54 20.32444 2/5/2007 ED N
19 Himagirish M 34 953847C 179 3 2034 163 53 19.94806 3/7/2007 ED N
20 MahendranM 46 046235B 209 1 2214 165 71 26.07897 2/21/2007 CMC N
21 Renuka F 36 975795C 10 1 767 146 46 21.58003 3/10/2007 ED N
22 ManogaranM 53 897763C 236 3 2085 175 65 21.22449 3/7/2007 CMC N
23 Parimala F 25 163989c 279 2 861 155 61 25.39022 3/14/2007 CMC Y
24 KalaiselvanM 42 843529C 61 3 1880 160 52 20.3125 12/20/2006 CMC N
25 Kumar RajaM 40 934658C 155 1 2852 180 80 24.69136 2/14/2007 CMC N
26 Selladurai M 42 903114C 105 1 780 169 63 22.05805 1/10/2007 CMC N
27 Kamala V F 57 951153C 36 4 144 150 56 24.88889 1/4/2007 CMC Y
28 Hema BinduF 28 962977C 187 1 1504 155 40 16.64932 2/20/2007 CMC N
29 Tamil Selvi F 44 989092C 125 2 2254 146 51 23.92569 3/13/2007 CMC N
30 ChandrakalaF 32 668652C 179 1 1400 157 48 19.47341 3/27/2007 CMC N
31 Karuna M F 37 464999C 122 1 1760 172 52 17.57707 4/7/2007 ED N
32 Sivaya M 47 977099C 36 4 752 160 53 20.70313 2/27/2007 CMC Y
33 JayachandranM 30 419035C 254 1 2340 167 76 27.25089 2/6/2007 CMC N
34 DamodaranM 47 521373C 255 1 1512 173 83 27.7323 3/13/2007 CMC N
35 Anita Pal F 27 101530C 268 1 1652 150 62 27.55556 11/29/2006 CMC N
36 ChandrasekharM 38 720082C 119 1 468 165 75 27.54821 4/18/2007 CH N
37 ThenmozhiF 26 92888C 119 1 900 153 45 19.22338 3/28/2007 CMC N
38 Mahesh K M 33 994350C 119 1 1920 175 58 18.93878 2/28/2007 TIR N
39 ParasuramanM 40 984239C 118 4 540 4/10/2007 ED Y
40 Indira F 36 652471B 94 4 1404 165 44 16.16162 5/16/2007 ED N
41 RanganathanM 38 802697C 212 1 2310 165 56 20.56933 5/22/2007 CMC N
42 Rani G F 36 998352C 44 4 44 156 36 14.7929 4/13/2007 Athoor Y
43 Samudralal PrasadM 29 988933C 7 4 560 170 35 12.11073 3/19/2007 CMC Y
44 Shivamani M 34 968987C 135 1 2024 171 62 21.20311 4/26/2007 ED N
45 Nand KishoreM 55 000838D 161 1 872 170 59 20.41522 4/5/2007 CMC N
46 JayaramanM 46 777345C 252 2 2340 168 59 20.9042 5/2/2007 CMC N
47 Dil Shad F 35 016300D 40 2 968 159 50 19.7777 5/4/2007 CMC N
48 Prakash M 30 017296D 75 2 154 166 57 20.68515 5/12/2007 TIR N
49 Kumar G M 35 499155B 52 1 3420 162 63 24.00549 6/6/2007 CMC N
50 Sellamal F 67 042207D 148 1 828 146 50 23.45656 6/13/2007 CMC N
51 GarudachallamM 40 047080D 61 3 931 158 46 18.42653 6/22/2007 CMC Y
52 Kumari F 29 050437D 75 1 1716 153 58 24.7768 6/27/2007 CMC N
53 Gopal M 40 051627B 249 3 1088 159 55 21.75547 8/6/2007 ED N
54 Ravi ShankarM 45 062480D 116 4 960 165 40 14.69238 7/20/2007 CMC Y
55 Bhumanani JansiF 38 058837D 154 3 1122 153 43 18.369 8/31/2007 TIR Y
56 Sanjoy MondalM 34 992022C 218 1 1140 171 63 21.54509 8/22/2007 CMC N
57 Raju GS M 31 908110C 346 3 2706 156 62 25.47666 6/14/2007 TIR Y
58 Siva Prasad ReddyM 55 105530C 309 1 2356 170 78 26.98962 1/5/2007 CMC N
59 Ramesh S M 38 893199C 190 3 1386 174 76 25.10239 11/1/2006 CMC Y
60 Shanti F 37 984485C 52 4 2448 151 34 14.91163 3/16/2007 CMC N
61 Subramani M 54 005743D 60 4 700 165 56 20.56933 5/9/2007 CMC Y
62 ViswanathanM 38 030704D 177 1 4459 165 68 24.97704 6/7/2007 CMC N
63 Kannan M 55 079647D 151 1 1274 163 60 8/29/2007 8/29/2007 CMC N
64 Suresh BabuM 32 039249D 135 1 744 170 75 25.95156 8/1/2007 CH N
65 Srinivasa RaoM 40 036722D 71 4 1368 167 58 20.79673 7/18/2007 CMC Y
66 Ponnaiyan M 39 007185D 165 4 2106 167 57 20.43817 5/2/2007 CMC N
67 Mohana KumarM 35 072659d 182 4 1311 170 53 18.3391 9/5/2007 CMC Y
68 ChandrasekharM 36 059506D 24 4 450 170 52 17.99308 8/22/2007 Cud Y
69 Nithur M 33 027814D 69 4 1224 160 28 10.9375 10/3/2007 CMC Y
70 Prassanna F 43 949385C 42 4 180 155 55 22.89282 10/3/2007 CMC Y
71 Anitha F 29 054988D 36 4 1000 146 40 18.76525 9/26/2007 ED N
72 Arjunan M 38 957015C 157 4 1170 173 52 17.37445 9/1/2007 Coim Y
73 SamadhanamF 38 99 1 1260 166 72 26.12861 10/3/2007 CMC N
74 Fouzia F 31 380058B 196 1 1120 150 63 28 9/5/2007 CMC N
75 Kalpana V F 29 016950D 72 4 1296 160 55 21.48438 5/23/2007 CMC N
76 Chinmoy M 30 986182C 109 4 1600 63 #DIV/0! 3/9/2007 CMC Y
77 Krishna M M 29 884539C 186 3 180 161 52 20.06095 2/14/2007 Tir Y
78 Hiradaya M 51 954331C 109 4 416 163 61 22.95909 4/1/2007 CMC N
79 Tamil Selvi F 45 989092C 125 1 2254 146 51 23.92569 3/13/2007 CMC N
80 Anand BabuM 37 370333C 51 3 1134 54 #DIV/0! 3/13/2007 CMC N
81 Ashish KumarM 39 023906D 40 3 336 170 66 22.83737 5/18/2007 CMC Y
82 Venugopal M 33 922626C 241 1 2769 173 56 18.71095 10/31/2007 CMC N
83 NagabhooshnamM 40 239758c 183 1 1833 74 #DIV/0! 11/16/2006 TIR Y
84 Ananthi F 31 896338B 184 1 988 165 47 17.26354 10/12/2007 ED Y
85 Jamuna F 45 897228C 4 1260 143 33 16.13771 3/7/2007 ED Y
86 Obul R M 30 951030C 253 4 1736 169 49 17.15626 2/1/2007 Cud Y
87 Hema N F 32 091909D 8 4 882 154 43 18.13122 10/1/2007 Tir Y
88 Elappan M 38 521991C 280 2 2848 170 75 25.95156 10/18/2007 ED N
89 Pandu RanganM 30 984892C 200 3 1484 169 50 17.50639 11/12/2007 ED Y
90 Saravanan M 32 352062C 229 2 2944 170 80 27.68166 10/4/2007 ED Y
91 Chitti Babu M 37 536199C 96 4 672 163 52 19.57168 10/23/2007 ED Y
92 Senthil KumarM 34 851286C 229 3 3290 170 70 24.22145 11/2/2007 SAL Y
93 SambaMoorthyM 40 702981C 71 3 969 61 #DIV/0! 10/12/2007 CMC Y
94 Basheer AhmedM 33 288229C 161 2 2006 174 73 24.11151 11/1/2007 ED N
95 DeenadayalanM 34 818077B 10 4 372 162 44 16.76574 11/3/2007 CMC Y
96 Lalitha F 46 105512D 67 4 918 153 45 19.22338 10/31/2007 CMC N
97 Srinivasan M 42 104880d 89 4 1584 156 54 22.18935 10/27/2007 Cud N
98 Kannu P M 76 818065C 168 4 1140 174 50 16.51473 8/7/2007 CMC Y
99 Jothi S M 58 971713C 227 1 781 168 70 24.80159 7/7/2007 CMC Y
100 Munindra M 40 101515D 124 3 594 173 56 18.71095 10/15/2007 CMC Y
101 Sabita Dey M 48 016754D 64 4 484 165 56 20.56933 5/1/2007 CMC N
102 Vijaykumar M 33 171596C 8 4 605 168 40 14.17234 10/11/2007 CMC N
103 AnnalakshmiF 23 348543C 4 999 142 33 16.3658 9/21/2007 ED N
104 Isaac M 64 975684C 98 4 960 168 50 17.71542 4/30/2007 TIR Y
105 Srinivasan M 36 756645C 106 4 2160 159 49 19.38214 7/1/2007 Cud Y
106 PadmanabhanM 29 998133C 73 1 798 165 59 21.67126 3/29/2007 Tir N
107 Shanta ManiF 45 017497d 118 4 1640 157 45 18.25632 10/26/2007 Coim Y
108 Indra F 28 118371D 240 4 1125 150 37 16.44444 11/14/2007 ED Y
109 Rani C F 49 994498C 64 4 1044 155 43 17.89802 11/12/2007 ED Y
previous OIdate of diagnosistreatment ongoing? no. of days completedtype of HAARTI IS Y/N last visit days of follow upyears of follow upfollow up complete
1.1 8/21/2006 ATT Y 75.00 3 N 7/31/2007 269.00 0.5 Y
4 N 3/7/2007 123.00 0.5 Y
4 11/3/2006 N 29.00 1 N 6/5/2007 185.00 0.5 Y
1.4 1/17/2006 ATT N 288.00 1 N 10/24/2007 357.00 0.5 Y
2 N 10/10/2007 231.00 0.5 Y
1 N 6/13/2007 210.00 0.5 Y
4 N 11/19/2007 369.00 0.5 Y
4 N 5/22/2007 194.00 0.5 Y
4 11/2/2006 Gan Y 15.00 1 N 1/5/2007 49.00 0.134247 N
1.1 3/1/2006 ATT N 277.00 ? N 1/3/2007 31.00 0.084932 N
3 N 1/17/2007 14.00 0.038356 N
1.4 1/4/2007 ATT Y 20.00 4 N 4/11/2007 77.00 0.210959 Exp
1.2 9/1/2006 ATT Y 144.00 4 N 9/7/2007 227.00 0.5 Y
1 N 9/5/2007 203.00 0.5 Y
1 N 3/10/2008 427.00 0.5 Y
1.4 11/17/2006 ATT Y 34.00 3 N 4/16/2008 482.00 0.5 Y
1.2 3/21/2007 ATT Y 83.00 2 ? 9/12/2007 92.00 0.252055 Exp
2 N 4/21/2008 441.00 0.5 Y
1 N 9/29/2007 206.00 0.5 Y
1 N 1/23/2008 336.00 0.5 Y
1 N 9/5/2007 179.00 0.5 Y
1 N 8/1/2007 147.00 0.5 Y
1.1 1/1/2002 ATT N 1898.00 4 N 4/16/2008 399.00 0.5 Y
3 N 12/26/2007 371.00 0.5 Y
1 N 7/19/2007 155.00 0.5 Y
1 N 8/24/2007 226.00 0.5 Y
1.1 12/20/2006 ATT Y 15.00 3 N 2/1/2007 28.00 0.076712 Y
1 N 11/27/2007 280.00 0.5 Y
1 N 9/19/2007 190.00 0.5 Y
2 N 9/8/2007 165.00 0.5 Y
2 N 10/17/2007 193.00 0.5 Y
1.5 12/1/2006 ATT Y 88.00 3 N 11/21/2007 267.00 0.5 Y
1 Y 6/20/2007 134.00 0.5 Y
1 N 2/8/2008 332.00 0.5 Y
1 N 4/19/2008 507.00 0.5 Y
2 Y 8/8/2007 112.00 0.306849 Exp
1 N 12/5/2007 252.00 0.5 Y
2 N 9/12/2007 196.00 0.5 Y
1.2 3/13/2007 ATT Y 28.00 ? N 3/19/2008 344.00 0.5 Y
2 N 10/31/2007 168.00 0.5 Y
2 N 11/28/2007 190.00 0.5 Y
1.4 4/4/2007 ATT Y 9.00 ? N 5/20/2007 37.00 0.1 Exp
3 3/5/2007 Bac N 14.00 1 Y 12/12/2007 268.00 0.5 Y
2 N 4/15/2008 355.00 0.5 Y
5 Y 4/28/2007 23.00 0.5 Y
1 N 1/27/2008 270.00 0.5 Y
1 N 4/16/2008 348.00 0.5 Y
2 N 6/15/2007 34.00 0.093151 N
2 N 2/20/2008 259.00 0.5 Y
2 N 2/13/2008 245.00 0.5 Y
1.2 12/15/2006 ATT N 189.00 1 ? 1/20/2008 212.00 0.5 Y
1 N 7/31/2007 34.00 0.093151 N
2 N 3/21/2008 228.00 0.5 Y
1.1 1/1/2005 ATT N 930.00 2 Y 4/21/2008 276.00 0.5 Y
1.4 7/25/2007 ATT Y 37.00 3 Y 4/16/2008 229.00 0.5 Y
2 N 9/7/2007 16.00 0.043836 N
1.4 3/1/2007 ATT Y 105.00 3 N 4/16/2008 307.00 0.5 Y
3 N 10/24/2007 292.00 0.5 Y
1.3 9/20/2006 ATT Y 42.00 4 N 4/8/2008 524.00 0.5 Y
1 N 9-Apr 390.00 0.5 Y
3 4/11/2007 Bac Y 28.00 1 N 4/8/2008 335.00 0.5 Y
5 Y 7/4/2007 27.00 0.073973 Y
2 N 3/19/2008 203.00 0.5 Y
2 N 4/16/2008 259.00 0.5 Y
1.4 6/9/2007 ATT Y 39.00 5 N 2/6/2008 203.00 0.5 Y
1 N 4/16/2008 350.00 0.5 Y
1.4 7/26/2007 ATT Y 41.00 3 N 5/1/2008 0.00 0.5 Y
1.1 7/18/2007 ATT Y 35.00 3 N 12/26/2007 126.00 0.345205 N
1.4 5/23/2007 ATT Y 133.00 3 N 10/26/2007 13.00 0.03 N
5/1.4 7/1/2007 ATT/flu Y 94.00 5 Y 0.5 Y
1 N 3/26/2008 0.5 Y
1.4 1/11/2007 ATT N 233.00 2 Y 2/6/2008 158.00 0.5 Y
1 N 4/23/2008 203.00 0.5 Y
2 N 9/26/2007 21.00 0.057534 N
2 N 10/17/2007 147.00 0.5 Y
7 3/2/2007 acyc N 7.00 3 N 6/5/2007 88.00 0.241096 N
8 9/15/2006 Bac N 152.00 2 N 5/11/2007 86.00 0.235616 N
1 N 4/18/2007 17.00 0.046575 N
1 N 12/4/2007 266.00 0.5 Y
1 N 27-Nov 259.00 0.5 Y
1.6 4/25/2007 ATT Y 23.00 5 Y 3/9/2008 296.00 0.5 Y
2 N 1/30/2008 91.00 0.249315 N
1.1 1/1/2002 ATT N 1780.00 2 N 10/3/2007 321.00 0.5 Y
1.1 3/22/2007 ATT N 204.00 1 N 4/2/2008 173.00 0.5 Y
1.4 10/11/2006 ATT Y 147.00 3 N 3/14/2007 7.00 0.019178 N
8 12/27/2006 Bac N 36.00 ? N 4/3/2008 427.00 0.5 Y
1.4 9/28/2007 ATT 3.00 ? N 4/15/2008 197.00 0.5 Y
1 N 1/9/2008 83.00 0.227397 N
1.1 3/7/2007 ATT N 250.00 2 N 4/16/2008 156.00 0.5 Y
1.1 9/3/2007 ATT Y 31.00 2 N 4/23/2008 202.00 0.5 Y
1.4 3/22/2007 ATT Y 215.00 4 N 3/3/2008 132.00 0.361644 N
1.3 9/17/2007 ATT Y 46.00 ? N 4/29/2008 179.00 0.5 Y
1.7 9/11/2007 ATT Y 31.00 3 N 2/20/2008 131.00 0.358904 N
1 N 4/29/2008 180.00 0.5 Y
1.8 3/8/2007 ATT Y 240.00 3 N 1/30/2008 88.00 0.241096 N
2 N 4/8/2008 160.00 0.5 Y
2 N 4/30/2008 186.00 0.5 Y
5 5/6/2006 flu N 458.00 2 Y 4/23/2008 260.00 0.5 Y
7 6/3/2006 acyc N 399.00 2 N 4/2/2008 270.00 0.5 Y
1.1 9/29/2007 ATT Y 16.00 2 ? 5/1/2008 199.00 0.5 Y
3 N 9/19/2007 141.00 0.5 Y
1 Y 12/26/2007 76.00 0.208219 Y
2 N 4/23/2008 215.00 0.5 Y
1.7 3/21/2007 ATT Y 40.00 ? N 4/30/2008 366.00 0.5 Y
1.4 3/14/2007 ATT Y 109.00 ? N 4/30/2008 304.00 0.5 Y
2 N 4/30/2008 398.00 0.5 Y
1.1 7/25/2007 ATT Y 93.00 2 N 1/9/2008 75.00 0.205479 N
1.6 10/22/2007 ATT N 23.00 1 Y 12/18/2007 34.00 0.093151 Y
1.2 4/11/2007 ATT N 215.00 1 Y 4/8/2008 148.00 0.5 Y
Name Hosp no. age sex Stage CD41 CD42 VL1 VL2
Arjunan 957015C 38 M 4 154 175
Gaudachalam047080C 40 M 3 61 ?
Jamuna 609862C 41 F 4 88 116
Jayachandran419035c 32 M 1 254 648
Samudrala 988933C 29 M 4 7 161
Viswanathan030704D 38 M 1 177 626
Ravi Shankar062480D 45 M 4 116 151
Ashish K 023906D 39 M 3 40 1020
Nandkishore000838D 55 M 1 161 162
Munindra 101515D 40 M 3 124 169
Indra 118371D 28 F 4 240 617
Kannu P 818065C 76 M 4 168 ?
Prasanna 949385C 43 F 4 42 131
Bhuminani Jhansi058837D 38 F 3 154 418
Vijaykumar171596C 33 M 4 8 25
Chandrasekhar720082C 38 M 1 119 ?
Rani C 994498C 49 F 4 64 188
ALC base wt ht BMI prev OI Y/Ntype of OI 1type of OI2 date of OI Date of ART
1170 52 173 17.37445 Y 1.40 1/11/2007 9/1/2007
931 46 158 18.42653 Y 1.2 12/15/2006 6/22/2007
1504 41 150 18.22222 Y 1.1 8 3/21/2007 6/12/2007
2340 76 167 27.25089 N 2/20/2007
560 39 157 15.82214 Y 3 3/5/2007 3/19/2007
4459 68 165 24.97704 N 6/7/2007
960 40 164 14.8721 Y 1.1 1/1/2005 7/20/2007
336 66 170 22.83737 Y 1.6 4/25/2007 5/18/2007
872 59 170 20.41522 N 4/5/2007
594 56 173 18.71095 Y 1.1 9/29/2007 10/15/2007
1125 37 150 16.44444 Y 1.6 10/22/2007 11/14/2007
1140 50 174 16.51473 Y 5 7 5/6/2006 8/7/2007
180 55 160 21.48438 Y 5 1.4 7/6/2007 8/17/2007
1122 43 153 18.369 Y 1.8 7/25/2007 8/31/2007
40 168 14.17234 N 10/31/2007
468 75 165 27.54821 N 4/18/2007
1044 43 155 17.89802 Y 1.2 4/11/2007 11/12/2007
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
Date of IRIS ART-OI IRIS-ART type of IRISImp/died IRIS/IRSLStype of ART
9/16/2007 233 15 1.40 Imp Y 2
6/29/2007 7 6.00 Imp ? 2
8/28/2007 83 77 ?TBM died ? 2
6/20/2007 120 1.1 Imp Y 2
4/27/2007 14 39 4 imp Y 1
7/4/2007 27 7 Imp Y 5
7/24/2007 930 4 9 Imp Y 2
5/24/2007 23 6 1.4/1.6 Imp Y 5
4/10/2007 5 1.2 Imp Y 5
10/20/2007 16 5 1.1 Imp ? 4
12/18/2007 23 34 1.6 Imp Y 1
9/5/2007 458 29 1.1 Imp Y 2
9/1/2007 42 15 4.1 Imp Y 5
31/9/2007 37 30 1.9 Imp Y 3
12/26/2007 56 1.4 Imp Y 1
4/25/2007 7 10.0 died Y 2
2/8/2008 215 88 1.1 ? Y 1
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0
0
0
0
0
0
0
0
0
0
0
0
0
